European Neuropsychopharmacology (v.16, #S4)
P.4.a.005 Should the duration requirement for generalized anxiety disorder be changed? - Evidence from the national comorbidity survey replication by H.U. Wittchen; R.C. Kessler; N. Brandenburg; M. Lane; P. Roy-Byrne; P.D. Stang; D.J. Stein (S450).
P.4.a.003 Aripiprazole augmentation of fluvoxamine in poor-insight obsessive-compulsive patients by F. Panigada; L. Liperi; F.F. Siliprandi; G. Blaser; M. Locatelli; E. Smeraldi; C. Insacco (S450).
P.4.a.006 A fixed dose study of the efficacy and safety of duloxetine for the treatment of generalised anxiety disorder by H. Koponen; C. Allgulander; Y.L. Pritchett; J. Erickson; M.J. Detke; S. Ball; J.M. Russell (S451).
P.4.a.007 Natural course of obsessive compulsive disorder (OCD) over four years: findings from a prospective community study of adolescents and young adults by R. Lieb; L. Schwender; A. Nocon; H. Pfister; H.U. Wittchen (S451-S452).
P.4.a.008 A randomized placebo controlled trial of olanzapine in trichotillomania by M. Van Ameringen; C. Mancini; B. Patterson; M. Bennett; J. Oakman (S452).
P.4.a.002 Evaluation of a global anxiety-visual analogue scale in a clinical trial comparing lorazepam and paroxetine in patients with generalized anxiety disorder by V.S.L. Williams; D.E. Feltner; C.D. Hill; R.J. Morlock (S449).
P.4.a.001 A study of venlafaxine plus long-acting form of risperidone in patients with treatment-resistant obsessive compulsive disorder: preliminary results by S. Ozdemir; N. Kocabasoglu (S448-S449).
P.3.e.009 Cognitive enhancement in schizophrenia: the role of dopamine and noradrenaline in the prefrontal cortex by P. Lopez-Garcia; B. Snitz; K. Smedley; C.S. Carter (S446-S447).
P.3.e.008 Psychoeducation improves attitudes towards medication in schizophrenia by T. Wobrock; B. Behrendt; P. Falkai (S446).
P.3.f.001 Association study of the glycogen synthase kinase-3β (GSK-3β)-50T/C polymorphism with schizophrenia; association with depression and cognitive impairment by Y.H. Kim; J.G. Lee; S.J. Lee (S447).
P.3.f.002 The 5-HT6 receptor antagonists, SB271,046 and SB258,585, enhance social memory and cholinergic transmission in rats: a comparison with 5-HT1A receptor partial agonists by F. Loiseau; M.J. Millan; J.M. Rivet; A. Gobert; L. De Groote; D. Sicard; B. Di Cara; L. Cistarelli; R. Billiras; A. Dekeyne (S447-S448).
P.3.f.003 Repeated treatment of low doses phencyclidine causes spatial learning impairments in mice by S. Beraki; S.O. Ögren (S448).
P.4.a.009 Developmental trajectories of anxiety disorders in offspring at high risk for panic disorder by J. Biederman; C. Petty; D. Hirshfeld-Becker; A. Henin; B. Henry; S.V. Faraone; J.F. Rosenbaum (S452-S453).
P.4.a.010 Risk factors for generalized anxiety: a prospective-longitudinal epidemiological study of adolescents and young adults by K. Beesdo; H.U. Wittchen; M. Hoefler; R. Lieb; H. Pfister (S453).
P.4.a.019 Serotonin reuptake inhibition and dopamine receptor antagonism together buffer the blood pressure response to stress in social anxiety disorder by S.J.C. Davies; S.D. Hood; S.V. Argyropoulos; D.A. Hince; K. Morris; D.J. Nutt; J. Potokar (S458).
P.4.a.018 The effects of D-cycloserine on a cognitive function task under different states of anxiety in healthy volunteers by J.E. Bailey; A. Papadopoulos; D.J. Nutt (S457-S458).
P.4.a.020 Efficacy and safety of pregabalin for the treatment of generalized anxiety disorder in elderly patients by S.A. Montgomery; K. Chatamra; F. Baldinetti; E. Whalen (S458-S459).
P.4.a.021 Sleep in obsessive-compulsive disorder: a comparative study with “non-melancholic” depression by A. Matos-Pires; F. Arriaga (S459).
P.4.a.022 Association study of limbic system-associated membrane protein gene polymorphisms in panic disorder by E. Maron; K. Koido; A. Must; A. Reimets; S. Köks; E. Vasar; V. Vasar; J. Shlik (S459-S460).
P.4.a.017 Impaired recognition of fearful faces in generalized social phobia by M.J. Garner; D.S. Baldwin; B.P. Bradley; K. Mogg (S457).
P.4.a.016 Alcohol consumption in first stages of panic disorder: relationships with symptoms and impairment by B. Rodríguez-Cabo; A. Herrán; M.L. Ramírez; M. Carrera; A. Ayestarán; D. Sierra-Biddle; F. Hoyuela; J.L. Vázquez-Barquero (S456-S457).
P.4.a.012 Should excessive worry be required for a diagnosis of generalized anxiety disorder? - Results from the US national comorbidity survey replication by A.M. Ruscio; W.T. Chiu; P. Roy-Byrne; P.E. Stang; D.J. Stein; H.U. Wittchen; R.C. Kessler (S454).
P.4.a.011 Longitudinal course of posttraumatic stress disorder and posttraumatic stress disorder symptoms in a community sample of adolescents and young adults by A. Perkonigg; H. Pfister; M.B. Stein; M. Hoefler; R. Lieb; A. Maercker; H.U. Wittchen (S453-S454).
P.4.a.013 Generalized anxiety and pain: cross-sectional associations and implications by K. Beesdo; F. Jacobi; H.U. Wittchen (S455).
P.4.a.014 Association and temporal relation of generalized anxiety and pain in the first three decades of life: a 10-year follow-up study among adolescents and young adult by K. Beesdo; H.U. Wittchen; A. Guenther; R. Lieb (S455-S456).
P.4.a.015 Efficacy of isolated treatment components in generalized anxiety disorder: worry exposure versus applied relaxation by J. Hoyer; K. Beesdo; J. Junge; E.S. Becker (S456).
P.3.e.007 Risperidone oral solution, therapeutic possibility in treatment of acute and agitated psychotic patients by D. Lasic; G. Rubesa; G. Dodig; Z. Katavic; T. Glavina; M. Zuljan-Cvitanovic (S445-S446).
P.3.e.006 Measurements of reaction time in clinical practice by B. Kores Plesnicar (S445).
P.3.d.012 The response of clozapine on midbrain dopamine neurons depends on endogenous concentration of kynurenic acid by L. Schwieler; K.R. Linderholm; L.K. Nilsson; G. Engberg; S. Erhardt (S435-S436).
P.3.d.011 In vitro and in vivo characterization of glycine transporter type-1 by two inhibitors, Org-24461 and NFPS by B. Marko; G. Szabo; S. Udvari; M. Agoston; E. Szabo; Z. Juranyi; A. Egyed; P. Matyus; L.G. Harsing (S435).
P.3.d.013 Correlation between acute atypical antipsychotic treatment and cognitive functioning in first episode psychosis by P. Fusar-Poli; M. Broome; P. Matthiasson; J. Woolley; L. Valmaggia; P. Tabraham; L. Johns; E. Bramon; S. Williams; M. Brammer; P. McGuire (S436).
P.3.d.014 Anti-S100 antibodies ameliorate haloperidol-induced catalepsy and do not change the activity of haloperidol in apomorphine-induced stereotypy by J.L. Dugina; I.A. Kheifez; A.V. Martyushev-Poklad; T.A. Voronina; G.M. Molodavkin; O.I. Epstein; S.A. Sergeva (S436-S437).
P.3.d.015 Effect of quetiapine on reversing the decrease in tyrosine hydroxylase immunoreactivity following by chronic treatment of haloperidol in rat caudate putamen by Y.B. Zhang; H.Y. Xu; X.M. Li (S437).
P.3.d.010 Neonatal endotoxin administration induces behavioural changes in young adult rat males: implications for the etiopathogenesis of schizophrenia by H. Tejkalová; J. Klaschka; F. Štastný (S434-S435).
P.3.d.009 F15063, a novel antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: II. Profile in models predictive of efficacy against positive, negative symptoms and cognitive deficits of schizophrenia by R. Depoortere; L. Bardin; A.L. Auclair; L. Bruins Slot; M.S. Kleven; A. Newman-Tancredi (S434).
P.3.d.005 Effects of novel antipsychotics with preferential activity at D2-like and 5-HT1A receptors, in comparison with typical and atypical reference antipsychotics, in rodent models of cognition and memory deficit by L. Bardin; A. Newman-Tancredi; R. Depoortere (S431-S432).
P.3.d.004 F15063, a novel antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: I. Receptor affinity and efficacy in vitro and activity in neurochemical and neuroendocrine tests in rodents by A. Newman-Tancredi; M.B. Assié; J.C. Martel; C. Cosi; P. Heusler; L. Bruins Slot; E. Carilla-Durand; D. Cussac (S431).
P.3.d.006 Pharmacological profile of RGH-188, a novel dopamine D3/D2 receptor antagonist/partial agonist atypical antipsychotic by I. Gyertyán; B. Kiss; K. Sághy; I. Laszlovszky; A. Horváth; J. Laszy; É. Schmidt; G. Szabó; G. Domány; É. Ágai Csongor; K. Tihanyi; Z. Szombathelyi (S432).
P.3.d.007 F15063, a novel antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: III. Duration of brain D2-like receptor occupancy, antipsychotic-like activity and plasma concentration in rodents by M.B. Assié; L. Bardin; A.L. Auclair; N. Consul-Denjean; F. Sautel; M.S. Kleven; R. Depoortere; A. Newman-Tancredi (S432-S433).
P.3.d.008 Effects of novel antipsychotics with preferential activity at D2-like and 5-HT1A receptors, in comparison with typical and atypical reference antipsychotics, in rodent models of cognitive flexibility and sensory-motor gating by A.L. Auclair; A. Newman-Tancredi; R. Depoortere (S433).
P.3.d.016 Effects of aripiprazole/OPC-14597 on pharmacological models of psychosis in rats by R.E. Nordquist; M. Maco; C. Freichel; C. Riemer; W.P. Spooren (S438).
P.3.d.017 Effect of first generation antipsychotic treatment on oxidative stress markers in schizophrenia by A. Mechri; C. Fendri; L. Ben Othman; A. Mekhinini; A. Kerkeni; L. Gaha (S438).
P.3.e.002 Clinical evaluation of levopromazine (methotrimeprazine) as add-on therapy in fibromyalgia management by P. Morillas-Arques; C.M. Rodriguez-Lopez; J.S. Vilchez; J. Hidalgo; F. Rico-Villademoros; E.P. Calandre (S442-S443).
P.3.e.001 Impact of the obesity on the use of antipsychotic drugs in a Spanish adult population setting by A. Sicras Mainar; M. Blanca Tamayo; R. Navarro Artieda; J. Serrat Tarres; J. Rejas Gutierrez; J.R. Llopart Lopez (S442).
P.3.e.003 Dissociation of working memory from decision-making in schizophrenia by Y.S. Kweon; K.U. Lee; S.J. Lee; Y.T. Kim; S.H. Kim; S.H. Jeung; H.K. Lee; J.T. Lee (S443-S444).
P.3.e.004 Pharmacokinetics of quetiapine: evidence from a routine therapeutic drug monitoring service by I. Castberg; E. Skogvoll; O. Spigset (S444).
P.3.e.005 Influencing negative symptoms of schizophrenia with repetitive transcranial magnetic stimulation: a pilot study by R. Prikryl; L. Ustohal; T. Kasparek; H. Kucerova; E. Ceskova; S. Skotakova (S444-S445).
P.3.d.023 Efficacy of a psychoeducational program for weight loss in patients who have experienced weight gain during treatment with olanzapine by S. Castrogiovanni; M. Simoncini; N. Iovieno; D. Cecconi; G. Dell' Agnello; P. Donda; M. Quadrigli; A. Rossi; M. Mauri (S441-S442).
P.3.d.022 What combination of pharmacological effects can explain the partial reversal of PCP-disrupted social interaction in rats by atypical antipsychotics? by B.A.M. Biemans; H. Duytschaever; D. Ashton; B. Pouzet (S441).
P.3.d.018 Estimating extrapyramidal syndrome-inducing liability of antipsychotics in rodent behavioural models by K. Sághy; I. Gyertyán (S439).
P.3.d.019 Chronic olanzapine treatment affects intracellular signalling in selected subcellular compartments of rat prefrontal cortex by F. Fumagalli; A. Frasca; M. Spartà; F. Drago; G. Racagni; M.A. Riva (S439-S440).
P.3.d.020 Prolactin response to oral and long-acting forms of risperidone in schizophrenic patients by F. Duval; N. Chokmani; M.C. Mokrani; J. He; J.P. Macher (S440).
P.3.d.021 Physostigmine reverses MK-801-induced but not amphetamine-induced effects on latent inhibition: focus on cholinergic treatments in schizophrenia by S. Barak; I. Weiner (S440-S441).
P.4.b.001 Anxiolytic and reward-related properties of URB597, a novel FAAH inhibitor, in CD1 mice by E. Ognibene; W. Adriani; G. Laviola (S460).
P.4.b.002 The central neuropeptide S system: expression, pharmacology and behavioural significance of neuropeptide S receptors by S.K. Leonard; E. Kouranova; C. Bender; J.E. Malberg; L.E. Schechter; B. Luo; B. Platt; L. Potestio; C.E. Beyer; S. Rosenzweig-Lipson; R.H. Ring (S460-S461).
P.5.a.010 The effect of memantine on distinct behaviour syndromes in moderate to severe Alzheimer's disease patients by A. Blau; J.L. Cummings; J.T. Olin (S481).
P.5.a.009 Effects of long term treatment with cholinesterase inhibitors on sleep EEG in patients with dementia of Alzheimer and frontotemporal type by U.M. Hemmeter; R. Rocamora; A. Thum; M. Giesler; A. Haag; A. Becker; J.C. Krieg (S480-S481).
P.5.a.011 Efficacy and safety of donepezil in vascular dementia:results from the largest double-blind trial in vascular dementia patients by G. Roman; S. Black; D.R. Royall; I. Surick; D. Kumar; R. Schindler; H. Posner (S481-S482).
P.5.b.001 The role of hippocampal phospholipase A2 in memory retrieval in rats by E.L. Schaeffer; W.F. Gattaz (S482).
P.5.b.002 Magnetic resonance spectroscopy in patients with alcoholic dementia by H.J. Go; Y.H. Cheon; K. Ahn; Y.D. Kim; D. Kim (S482-S483).
P.5.a.008 Validity of clinical dementia rating and mini-mental state examination as a measure to assess the progression of Alzheimer's disease by I.H. Choo; D.Y. Lee; J.C. Youn; J.H. Jhoo; K.W. Kim; J.I. Woo (S480).
P.5.a.007 The validity of the cognitive and behavioural assessment tools for the Korean long-term care system by N. Hong; B.K. Yeon; H.C. Kim; S.G. Ryu; C.H. Han (S479).
P.5.a.003 Effect of functional diet BT-11 (Polygala tenuifolia Willdenow) on subjective memory impairment and mild cognitive impairment in older people by S.H. Kim; H.Y. Jung; J.S. Yi; J.Y. Lee; K.Y. Shin; G.H. Lee; Y.H. Suh; Y.S. Kim (S477).
P.5.a.002 Relationships between writing errors and cognitive impairment in elderly psychiatric patients by S.C. Tamasan; D. Reisz (S476-S477).
P.5.a.004 Validity of the Korean version of the Mini-Cog by Y.M. Choi; D.W. Lee; J.Y. Lee (S477-S478).
P.5.a.005 Possible benefits of valproate addition to donepezil treatment in Alzheimer's disease by A. Borkowska; M. Tomaszewska; M. Wilkosc; W. Drozdz; A. Cichosz; J.K. Rybakowski (S478).
P.5.a.006 Impact of Apo-E genotype on the response to donepezil therapy in patients with Alzheimer's disease by M.G. Scordo; F. Varsaldi; M.G. Arena; M.L. Villa; G. Lombardi; F. Cordici; M.L. Dahl (S478-S479).
P.5.b.003 Assessing the effects of memantine in APP/PS1 transgenic mice by behavioural studies and ex vivo imaging of amyloid plaques using gadolinium labelled amyloid β peptides and μMRI by H. Scholtzova; Y.Z. Wadghiri; E.M. Sigurdsson; M. Douadi; Y. Li; D. Quartermain; P.K. Banerjee; T. Wisniewski (S483).
P.5.b.004 Effects of memantine on the activity of secretase enzymes in the human neuroblastoma cells by D.K. Lahiri; D. Chen; G.M. Alley; P.K. Banerjee (S483-S484).
P.5.e.002 An open-label study of quetiapine for delirium by N. Maneeton; B. Maneeton; M. Srisurapanont (S487-S488).
P.5.e.001 Does pneumoconiosis lead to cognitive dysfunction? by W.K. Tang; C.M. Lum; G.S. Ungvari; H.F.K. Chiu (S487).
P.5.e.003 Association of Alzheimer type dementia with hospital complications and health resource utilization in acute institutionalization by A. Sicras Mainar; R. Navarro Artieda; M. Blanca Tamayo; J.R. Llopart Lopez; N. Muro Perea; J. Rejas Gutierrez (S488).
P.5.e.004 A comparative study of haloperidol and quetiapine in the treatment of delirium: a preliminary randomized open label, flexible dose trial by Y. Lee; J. Lee; H.D. Rim; S.H. Kim; U.S. Chung; G.A. Cho; S.H. Won (S488-S489).
P.5.f.001 SSR180711, an α7 nicotinic receptor partial agonist, reverses memory deficits induced by β25-35 amyloid peptide icv administration in mice by A. Urani; O.E. Bergis; G. Griebel (S489).
P.5.d.002 Phospholipase D activation as a possible apoptotic signal in ischemic astrocytes by M. Krzystanek; I. Krupka-Matuszczyk; H.I. Trzeciak; E. Krzystanek (S486-S487).
P.5.d.001 Neuronal electrical high frequency stimulation enhances GABA release from human neocortical slices by M. Mantovani; V. Van Velthoven; H. Fuellgraf; T.J. Feuerstein; A. Moser (S486).
P.5.b.005 Memantine rescues cholinergic neurons from the neurotoxic effects of β-amyloid (Aβ1-42) by C. Nyakas; R. Szabó; B. Penke; P.G.M. Luiten; P.K. Banerjee (S484).
P.5.b.006 Age-dependent changes in hippocampal glutamate levels parallel learning impairment in APP/PS1 transgenic mice by R. Minkeviciene; J. Ihalainen; T. Malm; V. Keksa-Goldsteine; N. Leguit; J. Glennon; P.K. Banerjee; H. Tanila (S484-S485).
P.5.c.001 A 3-year open-label, follow-up study to evaluate the efficacy and tolerability of sarizotan in Parkinson's disease patients with treatment-associated dyskinesia by T. Müller (S485).
P.5.c.002 Hashimoto's encephalopathy following radioiodine (131I)-therapy of Graves' disease by J. Cordes; M. Dihné; F.J. Schuier (S485).
P.5.a.001 Galantamine in the treatment of Alzheimer's disease by K.L. Latalova; V. Pidrman (S476).
P.4.f.003 EPIA -anxiety as a trait in Slovakia by A. Heretik; V. Novotny; A. Heretik; J. Pecenak; A. Ritomsky (S475-S476).
P.4.c.003 Predictors of clinical outcome in panic disorder: a pooled analysis of venlafaxine extended release short-term treatment studies by M. Pollack; D.J. Stein; R. Mangano; R. Entsuah; N. Simon (S465-S466).
P.4.c.002 The effectiveness of 6-month treatment with citalopram in Korean panic disorder patients: a prospective, open-labelled, multi-centre trial by I.S. Lee; J.C. Yang; Y.C. Kim; H.D. Choe; B.H. Yu (S465).
P.4.c.004 Psychopharmacological drugs, anxiety and stress in premature coronary syndromes by J. Irurita; M. Irurita; C. Deniz; M.T. Martinez Saavedra; B. Ania; L. Lopez y Juan; C. Culebras; J.M. Saavedra; R. Chirino; F. Sanchez (S466).
P.4.c.005 Pregabalin's efficacy in achieving remission in outpatients with generalized anxiety disorder by H.U. Wittchen; F. Baldinetti (S466-S467).
P.4.d.001 Effect of ELB139, a subtype selectivie benzodiazepine agonist, on EEG in rats by B. Langen; K. Unverferth; C. Rundfeldt (S467-S468).
P.4.c.001 Adjunctive quetiapine for SRI-resistant obsessive compulsive disorder: a meta-analysis of three randomised controlled treatment trials by N.A. Fineberg; D.J. Stein; P. Carey; B. Vythilingum; T. Sivakumaran; S. Seedat; H. Westenberg; D. Denys; P. Premkumar (S464-S465).
P.4.b.008 Effect of cannabinoid CB1 receptor agonist WIN 55,212-2 in the elevated plus maze test: role of the serotonergic system by P. Fadda; M. Scherma; P. Salis; P. Mascia; L. Fattore; W. Fratta (S464).
P.4.b.004 Stimulation of the lateral habenula inhibits a panic-like behaviour by activation of serotonin-1A receptors in the rat dorsal periaqueductal gray by R.L.H. Pobbe; L.J. Bertoglio; H. Zangrossi (S461-S462).
P.4.b.003 Modulation of risk assessment and inhibitory avoidance behaviours by the dorsolateral periaqueductal gray in rats by L.J. Bertoglio; H. Zangrossi (S461).
P.4.b.005 Social housing in male mice - impact on experimental anxiety-related behaviour? by S.S. Arndt; M. Laarakker; R. Sommer; I. Lemmens; X. Fielmich; H.A. Van Lith; F. Ohl (S462).
P.4.b.006 Inhibition of nitric oxide synthase in the dorsolateral periaqueductal grey decreases behavioural consequences of predator exposure in rats by D.C. Aguiar; F.S. Guimaraes (S462-S463).
P.4.b.007 Dopamine receptor D4 gene polymorphism and personality traits in obsessive-compulsive disorder patients and in healthy controls by S.J. Kim; C.H. Kim; H.S. Lee (S463).
P.4.d.002 Which factors predict placebo response in anxiety disorders and major depression? by D.J. Stein; D.S. Baldwin; O. Dolberg; N. Despiegel; B. Bandelow (S468).
P.4.d.003 Brief exposure of mice to a predator induces memory impairment in the object recognition task-effects of acute and chronic treatment by diazepam and imipramine by V. Bertaina-Anglade; E. Enjuanes; C. Drieu la Rochelle (S468-S469).
P.4.e.005 The effect of acute tryptophan depletion on challenge induced anxiety in anxiety disorder patients is independent of a history of depression by S.D. Hood; S.V. Argyropoulos; S.J.C. Davies; D.A. Hince; C.J. Bell; D.J. Nutt; J. Potokar (S473-S474).
P.4.e.004 Trait stability and agoraphobia in a one year follow up panic disorder sample by F. Hoyuela; M. Carrera; M.M. Ramirez; B. Rodríguez-Cabo; A. Ayestarán; D. Sierra-Biddle; A. Herrán; J.L. Vázquez-Barquero (S472-S473).
P.4.e.006 A pooled analysis of the effects of 7.5% CO2 inhalation in healthy participants: a useful model of human anxiety? by J.E. Bailey; A. Papadopoulos; D.J. Nutt (S474).
P.4.f.001 Differential behaviour in the marble-burying test does not predict behavioural differences in generalized anxiety disorder models by M. Costa; C.R.A. Costa; A.C. Gargano; E. Ledvinka-Filho (S474-S475).
P.4.f.002 Anxiolytic-like effect of the essential oil from cymbopogon citratus in experimental procedures in mice by C.R.A. Costa; A.C. Gargano; M. Costa (S475).
P.4.e.003 Non-verbal memory impairment in Korean obsessive-compulsive disorder patients with checking type compulsions by C.H. Kim; J.W. Kim; M. Koo (S472).
P.4.e.002 Deep brain stimulation of the ventral caudate nucleus in the treatment of obsessive-compulsive disorder and major depression by B. Aouizerate; C. Martin-Guehl; E. Cuny; D. Guehl; H. Amieva; A. Benazzouz; C. Fabrigoule; M. Allard; A. Rougier; B. Bioulac; J. Tignol; P. Burbaud (S471-S472).
P.4.d.004 A comparison of the anxiolytic-like efficacy of mechanistically-distinct compounds in animal behavioural models by D.G. Smith; T.D. Wolinsky; B. Nugent; P. Poon; N. Moore; C. Sanchez; C.J. Swanson (S469).
P.4.d.005 Pregabalin acts at calcium channel alpha2-delta type 1 proteins to prevent acute stress-induced increases in cerebellar cGMP by B.M. Campbell; J.L. Morrison; C. Taylor (S469-S470).
P.4.d.006 Is early treatment affecting antiobsessional response in obsessive-compulsive disorder? by B. Dell'Osso; E. Mundo; A. Ceralli; M. Russo; A.C. Altamura (S470).
P.4.e.001 Low frequency repetitive transcranial magnetic stimulation for the treatment of patients with posttraumatic stress disorder: a double-blind, sham-controlled study by J.M. Song; C.U. Pae; Y.J. Lee; W.M. Bahk; T.Y. Jun; W. Hahm; J.H. Chae (S470-S471).
P.3.d.003 A cross-sectional study of adiponectin in patients with schizophrenia by L. Hanssens; M. DeHert; D. Van Eyck; M. Wampers; A. Scheen; J. Peuskens (S430-S431).
P.3.d.002 Do second-generation antipsychotics disrupt decision-making abilities in schizophrenia? by O. Kelemen; O. Nagy; A. Máttyássy; I. Kiss; Z. Janka; S. Kéri (S430).
P.3.a.049 Amisulpride monotherapy for elderly non-demented patients with very-late-onset schizophrenia-like psychosis by C. Psarros; C.G. Theleritis; A. Politis; G.N. Papadimitriou; C.R. Soldatos (S391).
P.3.a.048 Insight in schizophrenia: clinical correlates and relationship to functioning by G.M. Gharabawi; C.A. Bossie; P. Bouhours; I. Turkoz; M. Kujawa (S390-S391).
P.3.b.001 Polymorphisms of dysbindin gene (DTNBP1) and schizophrenia in the Korean population by T.Y. Jun; W.M. Bahk; J.H. Chae; C.U. Pae; Y.E. Jung; B.W. Lee; S.K. Bang; Y.S. Woo (S391-S392).
P.3.b.002 Stereotypy in schizophrenic patients on atypical antipsychotics versus conventional neuroleptics by M. Morrens; W. Hulstijn; B.G.C. Sabbe (S392-S393).
P.3.b.003 Validation of visuospatial navigation as a measure of episodic memory in schizophrenia by P. Boyer; J.L. Phillips; L.J. Boulay; A. Labelle; A.A. Ledoux (S393).
P.3.a.047 Remission in schizophrenia: a comparison of 2 dose regimens of ziprasidone versus haloperidol in a 40-week core and 3-year double-blind continuation study by F. Rappard; A. Loebel; L. Warrington; C. Siu; J.A. Lieberman (S390).
P.3.a.046 Pseudophaeochromocytoma syndrome caused by clozapine therapy - a case report by T. Sobanski; G. Wagner; S. Schubert; I. Dafov (S389-S390).
P.3.a.042 Clinical course, social functioning, quality of life & medication tolerability in previously untreated patients with schizophrenia: 36-month results from the European schizophrenia outpatient health outcomes (SOHO) study by D. Novick; D. Suarez; J. Brown; I. Gasquet; J.M. Haro (S387-S388).
P.3.a.041 Delaying symptom recurrence in patients with schizophrenia treated with paliperidone extended-release tablets by M. Kramer; S. Kushner; U. Vijapurkar; P. Lim; M. Eerdekens (S387).
P.3.a.043 Neuropsychological measures for cognitive affective dysregulation in paranoid schizophrenia: implications for functional neuroimaging research by E.S. Haralanova; A. Beraldi; S.H. Haralanov; K. Fast (S388).
P.3.a.044 Tobacco, alcohol and cannabis use in Tunisian patients with schizophrenia by X. Laqueille; S. Ghodhbane; F. Nacef; Z. Choubani; M. Nehdi; S. Douki; A. Dervaux (S388-S389).
P.3.a.045 Weight gain among patients with chronic psychotic disorders: a one year follow-up study by M. Yildiz; C. Cerit; S. Candan (S389).
P.3.b.004 Evidence of a cortical disinhibition in schizophrenia: a transcranial magnetic stimulation study by C. Ben Amor; A. Galinowski; B. Gueguen; M.C. Bourdel; J.P. Olie; S. Douki; M.O. Krebs (S393-S394).
P.3.b.005 TC-5619: an a 7 neuronal nicotinic receptor-selective agonist with the potential to treat schizophrenia by T.A. Hauser; M. Bencherif; P.M. Lippiello; K.G. Jordan; G.J. Gatto (S394).
P.3.c.004 Screening for metabolic abnormalities in patients with schizophrenia treated with antipsychotics: are we doing enough? by R. Van Winkel; M. DeHert; D. Van Eyck; L. Hanssens; M. Wampers; A. Scheen; J. Peuskens (S398).
P.3.c.003 Olanzapine versus ziprasidone in parenteral administration in psychotic relapse of schizophrenia by C. Tudor; D. Ungureanu; M.D. Gheorghe (S397-S398).
P.3.c.005 Evaluation of the metabolic safety of aripiprazole by M. De Hert; D. Van Eyck; L. Hanssens; M. Wampers; A. Scheen; J. Peuskens (S399).
P.3.c.006 A pilot crossover study on QTc interval associated with olanzapine and risperidone by K.P. Su; C.L. Huang; H.B. Hsu; C.M. Pariante (S399-S400).
P.3.c.007 A well being programme (WSP) in severe mental illness. Reducing risk for physical ill-health: a post programme re-audit at 2 years by S. Smith; D. Yeomans; C.J. Bushe; C. Eriksson; T. Harrison; R. Holmes; L. Mynors-Wallace; H. Oatway; G. Sullivan (S400).
P.3.c.002 A hyperinsulimic euglycaemic clamp study investigating the in fluence of treatment with olanzapine or ziprasidone on glucose-metabolism in healthy subjects by J. Sacher; N. Mossaheb; N. Klein; C. Spindelegger; T. Geiss-Granadia; R. Lanzenberger; E. Lackner; C. Joukhadar; M. Mueller; S. Kasper (S397).
P.3.c.001 A randomized double blind clinical trial in famotidine adjuvant therapy in schizophrenia by D. Farzin; S.H. Hosseini; A. Shafaat (S396-S397).
P.3.b.006 Relationship between glutathione peroxidase activity, glutathione and selenium levels in schizophrenic patients by A. Mechri; A. Mekhinini; L. Ben Othman; C. Fendri; L. Gaha; A. Kerkeni (S394-S395).
P.3.b.007 Long-term improvement of subjective well-being of schizophrenia outpatients correlates with early effective treatment and social functioning by M. Lambert; B.G. Schimmelmann; D. Naber; A. Schacht; T. Wagner; J. Czekalla (S395).
P.3.b.008 Oxidative stress and neurodevelopmental abnormalities in schizophrenia by A. Mechri; C. Fendri; H. Slama; L. Ben Othman; A. Kerkeni; L. Gaha (S395-S396).
P.3.b.009 Loss of latent inhibition in ovariectomized female rats: possible link to the oestrogen hypothesis of schizophrenia by M. Arad; I. Weiner (S396).
P.3.a.040 Clinical symptomatology and long-term memory in schizophrenia by A.A. Ledoux; R. Westmacott; J.L. Phillips; P. Boyer (S386).
P.3.a.039 Onset of action of oral paliperidone extended-release tablets in patients with acute schizophrenia: pooled results from three 6-week controlled studies by M. Kramer; I. Nuamah; P. Lim; M. Eerdekens (S385-S386).
P.3.a.022 Beneficial effect of short-term testosterone adjuvant treatment for negative symptoms of male schizophrenia by Y.H. Ko; S.H. Joe; S.W. Jung; C.H. Lee; H.G. Jung (S376).
P.3.a.021 Examination of specific genetic aspects of the dopaminergic neurotransmission and neuronal plasticity in neurocognitive subgrouping of schizophrenia by I. Szendi; A. Juhász; G. Szekeres; C. Cimmer; G. Csifcsak; A.Z. Kovacs; A. Rimanoczy; G. Galsi; K. Boda; Z. Janka (S375-S376).
P.3.a.023 Infiuence of glycine on cognitive functions in schizophrenia by D. Strzelecki; J. Rabe-Jablonska (S376-S377).
P.3.a.024 Correlations between cerebrospinalfiuid kynurenic acid and monoamine metabolites in male patients with schizophrenia by S. Erhardt; C. Nordin; E. Skogh; E.G. Jonsson; L.K. Nilsson (S377).
P.3.a.025 Open-label randomized trial comparing the efficacy and tolerability of quetiapine and olanzapine in first episode psychosis in adolescents by M.J. Parellada; D. Moreno; A. Ruiz-Sancho; O. Medina; C. Arango (S377-S378).
P.3.a.020 Subgroups within schizophrenia differentiated by clinical and neurocognitive parameters by I. Szendi; C. Cimmer; G. Csifcsak; G. Szekeres; A.Z. Kovacs; G. Galsi; M. Racsmany; K. Boda; Z. Janka (S374-S375).
P.3.a.019 Efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients:results of a randomized, double-blind, 18-week trial by E. Sacchetti; A. Galluzzo; P. Valsecchi; F. Romeo; B. Gorini; L. Warrington (S374).
P.3.a.015 Elaboration on the association between urbanicity and schizophrenia by M. Shmushkevitz; M. Weiser; J. VanOs; A. Reichenberg; J. Rabinowitz; D. Nahon; E. Kravitz; G. Lubin; H.Y. Knobler; S. Noy; M. Davidson (S372).
P.3.a.014 Offsprings of parents and siblings of psychotic patients:a possible explanation for the persistence of psychosis by L. Cohen; M. Weiser; A. Richenberg; D. Nahon; S. Noy; M. Davidson (S372).
P.3.a.016 Pharmacotherapy in schizophrenic patients and quality of life of their family members by L. Trajanovic; O. Skakic; O. Zikic (S372-S373).
P.3.a.017 Deficient inhibition of return (IOR) in unmedicated patients with schizophrenia, but not in patients in risk for psychosis by E. Gouzoulis-Mayfrank; M. Shemirani; S. Hajsamou; S. Ruhrmann; T. Schnell; J. Daumann; F. Schultze-Luther; B. Hoppmann; K. Heekeren; K. Schnell (S373).
P.3.a.018 Vitamin D deficiency and impaired parathormone metabolism as a risk factor of low bone mineral density in patients with diagnosis of schizophrenia treated with second generation antipsychotics by A. Wyszogrodzka-Kucharska; J. Rabe-Jablonska (S373-S374).
P.3.a.026 Sexual side effects of antipsychoticcs and treatment adherence by M.C. García; M. Vidal; R. Ramos (S378).
P.3.a.027 In fluences of polymorphisms of beta adrenergic receptors in the psychopharmacological treatment of schizophrenia by I. Spellmann; M. Riedel; R.L. Musil; A. Douhet; S. Dehning; P. Zill; N. Müller; H.J. Möller; B. Bondy (S378-S379).
P.3.a.035 Psychoeducation and compliance in the treatment of the patients with schizophrenia by D. Degmecic; I. Požgain; M. Grgic; P. Filakovic (S383).
P.3.a.034 Negative symptoms of schizophrenia: analysis of a multinational, cross-sectional survey of physician perceptions by Y. Lecrubier; R. Perry; G. Milligan; O. Leeuwenkamp (S382-S383).
P.3.a.036 Association between polymorphisms of the 5HT2A receptor gene and positive symptom response to olanzapine treatment in patients with schizophrenia by L. Olajossy-Hilkesberger; B. Godlewska; M. Olajossy; H. Marmurowska-Michalowska (S384).
P.3.a.037 Quality of life in bipolar type I disorder and schizophrenia in remission:clinical and neurocognitive correlates by S. Brissos; V.V. Dias; A.I. Carita (S384-S385).
P.3.a.038 Insight and depressive symptoms in first episode psychosis by S. Aspiazu; J. Ruiz; A. Aldama; K. Haidar; M. Alonso; I. Ruiz; J.A. Micó; A. González-Pinto (S385).
P.3.a.033 Association between changes on the Negative Symptom Assessment-16 scale (NSA-16) and functional outcomes in schizophrenia by D.I. Velligan; M. Wang; G. Haig; S. Lancaster; T.N. Taylor; L. Alphs (S382).
P.3.a.032 Cognitive efficacy of quetiapine and olanzapine in early onset first episode psychosis by O. Robles; A. Zabala; M.J. Parellada; A. Ruiz; M.D. Moreno; M.T. Burdalo; C. Arango (S381-S382).
P.3.a.028 Cognitive correlates of proton magnetic resonance spectroscopy measures in patients with first-episode schizophrenia by B. Galinska; A. Szulc; E. Tarasow; B. Kubas; W. Dzienis; A. Czernikiewicz; J. Walecki (S379).
P.3.a.029 First psychotic episodes:predictive factors in a 3-years follow up study by M. Arrasate; C. Valcarcel; B. Farnandez de Corres; F. Ramirez; J.L. Figuerido; A. González-Pinto; M. Garcia (S380).
P.3.a.030 Evidence that the outcome of developmental expression of psychosis is worse for adolescents growing up in an urban environment by H.U. Wittchen; J. Spauwen; L. Krabbendam; R. Lieb; J. Van Os (S380-S381).
P.3.a.031 Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people by C. Henquet; L. Krabbendam; J. Spauwen; C. Kaplan; R. Lieb; H.U. Wittchen; J. Van Os (S381).
P.3.c.008 Weight change after switching from olanzapine tablets to olanzapine orally disintegrated tablets in obese patients with schizophrenia by B. Chawla; H. Luxton-Andrew (S400-S401).
P.3.c.009 Valproate and psychotropic drug interactions by J. Glen; J. Fleming; M. Herman; M. Chetty (S401).
P.3.c.045 Treatment of agitation caused by severe mental illness: data from the South London and Maudsley intensive care units trial evaluation (SLAMICUTE) study by V. Mantua; M.J. Travis; Z. Atakan; M.B. Isaac; M.T. Isaac; S. Smith; D. Gilbert; J. Komeh; A. Shaw; C. Sweeney; R.W. Kerwin (S420-S421).
P.3.c.044 Plasma antioxidant status in first psychotic episode patients before and after antipsychotic treatment by M.O. Rojas-Corrales; F. Mosquera; A. Aldama; C. González; A. González-Pinto; J.A. Micó (S420).
P.3.c.046 Effectiveness of aripiprazole versus olanzapine, quetiapine, or risperidone: sub-analysis of a large, randomized, naturalistic study (STAR) by L. Hanssens; G. L'Italien; R.N. Marcus; R. McQuade; W.H. Carson; J.N. Beuzen (S421).
P.3.c.047 Wellness program: a program for managing weight control in schizophrenia: one-year results from the Czech Republic by E. Kitzlerova; L. Motlova; E. Dragomirecka (S422).
P.3.c.048 Antipsychotic safety: should we believe in guinea-pigs by D. Barrocas; M. Abreu; L. Figueira (S422-S423).
P.3.c.043 Association of leptin gene polymorphism with antipsychotic drug-induced weight gain by S.H. Ryu; W.S. Jang; E.Y. Cho; S.K. Kim; D.S. Lee; K.S. Hong (S419-S420).
P.3.c.042 Zotepine-induced mania: two cases report by C.C. Liang; J.Y. Chen; T.T. Chen; Y.M. Bai (S419).
P.3.c.038 Switching from other second generation antipsychotics to zotepine in schizophrenic patients: an 12-week open-label study by J.Y. Chen; T.T. Chen; C.C. Lin; Y.M. Bai; B.J. Wu; C.H. Hung (S416-S417).
P.3.c.037 Haloperidol in combination with clozapine in treatment-refractory patients with schizophrenia by N. Mossaheb; J. Sacher; G. Wiesegger; N. Klein; C.J. Spindelegger; S. Asenbaum; R. Dudczak; S. Kasper (S416).
P.3.c.039 A comparative efficacy and safety study of long-acting injectable risperidone and risperidone oral tablets among hospitalized patients: 48-week randomized, single-blind study by Y.M. Bai; T.T. Chen; B.J. Wu; C.H. Hung (S417).
P.3.c.040 The comparison of efficacy between aripiprazole and haloperidol in treatment of chronic schizophrenia and schizoaffective disorder: results for 16-week clinical study by J.G. Kim; D.H. Cho; S.J. Lee; J.K. Lee; K.S. Wang; Y.I. Seo; S.J. Choi; M.J. Joo; H.D. Kim; K.H. Lee; Y.J. Kwon; K.R. Han (S417-S418).
P.3.c.041 −759 C/T polymorphism of the 5-HT2C receptor gene and antipsychotic drug-induced weight gain by S.H. Ryu; W.S. Jang; E.Y. Cho; S.K. Kim; D.S. Lee; T.S. Park; S.H. Oh; K.S. Hong (S418-S419).
P.3.c.049 Aggression and psychopathology in an acute psychiatric sample:clinical and therapeutic considerations by A. Colasanti; M. Rossattini; D. Moliterno; A. Natoli; M.C. Mauri (S423).
P.3.c.050 Psychopathology and metabolic syndrome (MS) in psychotic patients: the CLAMORS study by C. Arango; J. Bobes; P. Aranda; R. Carmena; M. Garcia-Garcia; J. Rejas (S423-S424).
P.3.c.058 Emotion recognition deficit in first-episode schizophrenic patients and atypical antipsychotics by G.P.A. Amminger; S.W. Werneck-Rohrer; H.N.A. Aschauer; J.E. Edwards; M.S. Schloegelhofer (S427-S428).
P.3.c.057 Gender difference in interaction between ADRA2A gene and ADRB3 gene on bone density among schizophrenic patients with exposure to antipsychotics by T.H. Lan; H.J. Chiu; T.M. Hu; K.M. Lin; E.W. Loh; M.Y. Lee; H.R. Sun (S427).
P.3.c.059 Clozapine and amisulpride in a treatment resistant schizophrenic patient with alcohol dependence and diabetes comorbidity by A. Dervaux; J. Cazali (S428-S429).
P.3.c.060 Selected metabolic parameters in patients from Psychiatric Hospital Pezinok by G. Almassyova (S429).
P.3.d.001 Effects of bifeprunox on the rat ventral tegmental area dopamine and dorsal raphe serotonin neuronal activity by L. Dahan; O. Mnie-Filali; J. Arnt; P. Hertel; N. Haddjeri (S429-S430).
P.3.c.056 Efficacy of ziprasidone in the treatment of schizoaffective disorder:an analysis of 2 fixed-dose, placebo-controlled trials by F. Rappard; L.E. Warrington; I. Lombardo; I. Loebel; R. Yang (S427).
P.3.c.055 Dopamine D3 receptor polymorphism associated with amisulpride response on negative symptoms of schizophrenia by S.Y. Huang (S426).
P.3.c.051 Is risperidone an atypical antipsychotic? by D. Marinkovic; S. Totic; M. Marjanovic (S424).
P.3.c.052 Quetiapine monotherapy is efficacious for depressive episodes of bipolar I and II disorder: a confirmatory double-blind study (BOLDER II) by M.E. Thase; W. Macfadden; R. McCoy; W. Chang; J.R. Calabrese (S424-S425).
P.3.c.053 Prevalence of aggressive episodes among ambulatory patients with schizophrenia: focus on past and recent events by J. Bobes; O. Fillat (S425).
P.3.c.054 Olanzapine, quetiapine, and risperidone in the treatment of first-episode psychosis: effectiveness and factors influencing adherence to treatment by J.P. McEvoy; D.O. Perkins; H. Gu; R.M. Hamer; J.A. Lieberman (S425-S426).
P.3.c.036 Clinical efficacy, body weight change and cardiac safety of zotepine in schizophrenic patients by W.W. Lin; H.K. Chen (S415-S416).
P.3.c.035 SNAP-25 gene polymorphisms and weight gain in schizophrenic patients treated with atypical antipsychotics by R.L. Musil; I. Spellmann; M. Riedel; A. Douhet; S. Dehning; K. Maino; P. Zill; N. Müller; H.J. Möller; B. Bondy (S415).
P.3.c.018 Genetic predictors of cognitive function and response to treatment in schizophrenia by A. Ertugrul; A.E. Anil Yagcioglu; N.D. Woodward; K. Jayathilake; H.Y. Meltzer (S406).
P.3.c.017 Adjunctive treatment with a dopamine partial agonist, aripiprazole for antipsychotic induced hyperprolactinemia by J.C. Shim; D.L. Kelly; D.U. Jung; Y.S. Seo; Y.H. Kim; R.R. Conley (S405-S406).
P.3.c.019 Patient compliance and efficacy of quetiapine treatment in schizophrenia: results of six-month follow-up study by K. Alptekin (S406-S407).
P.3.c.020 The changes in the QTc interval before and after the intramuscular haloperidol injection by Y.C. Park; H.L. Bae; D.H. Kim; J.H. Choi (S407).
P.3.c.021 Patterns of antipsychotic-induced weight change: 3-year results from the intercontinental schizophrenia outpatient-health outcomes (IC-SOHO) study by M. Dossenbach; Z. Pachecho; D. Toledo; R. Cornejo; T. West; A. Lowry (S407-S408).
P.3.c.016 Diabetes and impaired glucose tolerance in the treatment of schizophrenia - interim assessment of prevalence and investigation of genetic predictors by G.P. Reynolds; O. Yevtushenko; R.J. O'Neill; J. Doherty; S.J. Cooper (S405).
P.3.c.015 Pre-attentive processes and attention: effect of risperidone for 6 weeks in untreated patients with schizophrenia and correlation with disorganization by I. Amado; C. Daban; M.F. Poirier; M.C. Bourdel; D. Willard; P. Bouhours; H. Lôo; M.O. Krebs (S404-S405).
P.3.c.011 Three years of experience of risperidone long acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care by O.S. Niaz; P.M. Haddad (S402).
P.3.c.010 Asenapine safety and tolerability in acute schizophrenia: a placebo-and risperidone-controlled trial by S.G. Potkin; M. Cohen; J. Panagides; A. Jina (S401-S402).
P.3.c.012 Discontinuation rate of antipsychotic drugs in the treatment of first treated schizophrenia by J.C. Shim; B.M. Choe; Y.M. Jae; J.G. Kim; H.C. Kim; S.G. Kim (S402-S403).
P.3.c.013 The prevalence of bone mineral density loss in the Korean patients with chronic schizophrenia by J.C. Shim; D.U. Jung; S.H. Yoon; J.G. Kim; Y.M. Jae; B.M. Choe; H.C. Kim; S.G. Kim (S403).
P.3.c.014 Side effects of atypical antipsychotics - prediction factor for compliance by A. Baloescu; D. Vasile; M.D. Gheorghe; G. Grigorescu (S404).
P.3.c.022 Amelioration of symptomatology, Parkinsonism and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in schizophrenia by R.D. Strous; R. Stryjer; R. Maayan; G. Gal; D. Eisner; A. Weizman (S408-S409).
P.3.c.023 Comorbidity associated with the use of antipsychotic drugs: a population study in the primary care setting by M. Blanca Tamayo; A. Sicras Mainar; J. Rejas Gutierrez; R. Navarro Artieda; J. Serrat Tarres; M.A. Ruiz Diaz; N. Muro Perea (S409).
P.3.c.031 The effect of lifestyle intervention to prevent weight gain during treatment with atypical antipsychotic drugs - a randomized study by E.S. Klarås; J. Kovac; M. Plommon; P.M. Nilsson; A. Ostapowicz (S413).
P.3.c.030 Serotonin 2c receptor gene polymorphisms in association with extrapyramidal side-effects in schizophrenic patients by A. Günes; M.L. Dahl; E. Spina; M.G. Scordo (S412-S413).
P.3.c.032 Risperidone long acting im formulation in high risk of noncompliance bipolar patients by D. Vasile; O. Vasiliu; D. Ojog; M.D. Gheorghe (S413-S414).
P.3.c.033 FDG-PET and MRI imaging of the effects of sertindole in the striatum in schizophrenia by M.S. Buchsbaum; A. Gupta; M.M. Haznedar; E. Hazlett; K.W. Chu; K. Goldstein; C. Goodman; R. Newmark; Y. Torosjan; N. Bark; A. Wolkin (S414).
P.3.c.034 Comparing the use and outcomes of antipsychotics in the real world by A.M. Taylor; P. Shajahan; R. Carleton (S414-S415).
P.3.c.029 Correlation between plasma ghrelin concentration and risperidone induced weight gain in patients with schizophrenia by B.J. Kim; E.H. Kim; Y.H. Jin; C.S. Park (S412).
P.3.c.028 Effectiveness of aripiprazole versus standard of care treatment in patients with schizophrenia: the Schizophrenia Trial of Aripiprazole (STAR) study by R. Kerwin; G. L'Italien; L. Hanssens; R.N. Marcus; R. McQuade; W.H. Carson; J.N. Beuzen (S411-S412).
P.3.c.024 Negative and cognitive symptomatology improvement during aripiprazole treatment in chronic schizophrenia by M.D. Gheorghe; V.A. Voicu; D. Vasile; O. Vasiliu; G. Grigorescu (S409-S410).
P.3.c.025 Change of cognitive functions in switching of risperidone for chronic schizophrenic patients by T.Y. Kim; M.Y. Chung; H.G. Chung; J.H. Choi (S410).
P.3.c.026 Remission of tardive dyskinesia following the switch from clozapine to zotepine: 2-year follow-up by C.C. Lin; J.Y. Chen; Y.M. Bai; T.T. Chen; Y.C. Wang; Y.J. Liou; W.K. Lin (S410-S411).
P.3.c.027 Pattern of neuroleptic drug use in acute schizophrenia by D. Gruenler; C. Bunk; M. Specka; M. Gastpar; E. Davids (S411).
P.6.a.001 Efficacy and safety of aripiprazole for the treatment of craving and relapse prevention in dually diagnosed alcohol dependent subjects: a pilot study by G. Martinotti; M. Di Nicola; S. Andreoli; G. Di Maria; D. Reina; L. Janiri (S489-S490).
P.6.a.002 Lamotrigine in treatment of delirium tremens by G. Djokic; N. Zivkovic; D. Lazic; S. Jakulic; A. Dostanic (S490).
P.8.b.006 Involvement of α2-adrenoceptors in the local peripheral anti-hyperalgesic effect of carbamazepine by M. Tomic; S. Vuckovic; R. Stepanovic-Petrovic; N. Ugresic; M. Prostran; B. Boskovic (S566-S567).
P.8.b.005 Diabetes-induced salivation disorders are mediated via alteration of intracellular Ca2+ stores functioning by L.A. Kruglikov; O.V. Kopach; N.V. Voitenko; N.V. Fedirko (S566).
P.8.b.007 Gaboxadol does not generalise to other sleep-enhancing agents in drug discrimination in rats by L.M. McDonald; W.E. Sheppard; D. Tattersall; P.H. Hutson; S. Staveley; B. Sohal (S567).
P.8.b.008 Examination stress induced changes of natural killer cell activity and personality characteristics by B.W. Nam; J.S. Seo; S.W. Moon; E.J. Ryu (S567-S568).
P.8.b.009 Effectiveness of live versus remote training on rater training outcomes by J. Dries; P. Samuelson (S568).
P.8.b.004 Synergetic effect of P1 and muscarinic receptors activation - new mechanism of autoregulation of submandibular salivary cells? by N.V. Fedirko; O.V. Kopach; L.A. Kruglikov; N.V. Voitenko (S565-S566).
P.8.b.003 Computed studies on a 3-D model of human head comparing effectiveness and safety of ECT and TMS by T. Zyss; B. Sawicki; A. Krawczyk; J. Starzynski; R. Szmurlo; S. Wincenciak; M. Siwek (S565).
P.8.a.055 Attitudes toward psychiatry among medical students - factors associated to selection of psychiatry as a career by A. Herran; M. Carrera; A. Andres; M. Jalon; J.L. Vázquez-Barquero; J. Llorca (S563).
P.8.a.054 Zolpidem compared to flurazepam and placebo in alcoholics by M.J.K. Jakovcevska Kujundziska; V.L. Lazarova; N.C. Cadikovska; V.F. Filovska (S562).
P.8.a.056 Correlations of emotional-mnestic activity indices with separate brain metabolite contents relative to the hemisphere in the post-ischemic stroke patients by S.M. Kuznetsova; Z. Rozhkova; V. Kuznetsov; D. Shulzhenko; E. Danich (S563).
P.8.b.001 Prevalence rates of major mental disorders in mental health related facilities in Korea by S.J. Cho; J.I. Park; J.N. Bae; B.J. Hahm; J.Y. Lee; M.J. Cho (S563-S564).
P.8.b.002 Acetylcholine-mediated regulation of secretory cells is associated with calcium release from endoplasmic reticulum via InsPS-sensitive ion channels by O.V. Kopach; L.A. Kruglikov; N.V. Voitenko; N.V. Fedirko (S564-S565).
P.8.b.010 Study of Cloninger's dimension of personality in patients with mood disorders by M. Abd El Meguid; M. Kamel; A.N. Omar; Y. Abd El Razek (S568).
P.8.b.011 Familial risk and prodromal features of psychosis in adolescents aged 15-16 years in the northern Finland 1986 birth cohort by P.H. Mäki; J. Miettunen; A. Taanila; I. Moilanen; M. Joukamaa; E. Lauronen; P.B. Jones; J.M. Veijola (S569).
C.02.02 Understanding the complexities of treatment informed by new research by J. Cookson (S572-S573).
C.02.01 Should we develop ICD11th - a treatment revision of the classification of psychiatric disorders? by N. Sartorius (S572).
C.02.03 Guidelines for the clinician in the treatment of serious mental illness: focus on tolerability and long-term wellness by J. Newcomer (S573).
C.03.01 Can we only treat dopamine dysregulation? by R. Murray (S573).
C.03.02 Limitations of current treatments: Why do patients switch therapies? by P. Falkai (S573).
C.01.03 Sustained remission as new standard for outcome in schizophrenia, changing longterm prognosis earlier in its course by J. Kane (S571-S572).
C.01.02 New levels of outcome for first-episode patients treated with long-acting risperidone by R.A. Emsley (S571).
P.8.b.012 Hepatitis C, interferon and depression by G.J.O. Granada; S.R.J. Sanchez; A.V.T. Artaza; M.S.P. Morales; G.S.C. Galan (S569-S570).
P.8.b.013 Bipolar disorder alters peripheral benzodiazepine receptors by S. Baroni; I. Masala; G. Giannaccini; M. Catena; L. Bevilacqua; B. Dell'Osso; D. Marazziti (S570).
P.8.b.014 Effects of 5-HT-2 receptor blocker (naftidrofuryl) on CMS functional state in elderly post-stroke patients by S.M. Kuznetsova; O.L. Lukach (S570).
C.01.01 Tracking patient remission and outcomes and treatment delivery in schizophrenia by J. Van Os (S571).
P.8.a.053 A double-blind placebo-controlled study of adjunctive risperidone for treatment-resistant major depressive disorder by G.M. Gharabawi; C.M. Canuso; G.J. Pandina; C.A. Bossie; M. Kujawa; C. Kosik-Gonzalez; I. Turkoz (S562).
P.8.a.052 Suicide attempters, stress and peripheral benzodiazepine receptors by M. Catena; S. Baroni; I. Masala; B. Dell'Osso; A. Baldini; G. Giannaccini; D. Marazziti (S561).
P.8.a.035 Lorazepam-induced reduction in activity mirrors decrements in cognitive and psychomotor performance by J. Dawson; J. Boyle; N. Stanley; S. Johnsen; I. Hindmarch; D.J. Skene (S552-S553).
P.8.a.034 DSM-IV pain disorder in the general population - an exploration of the structure and threshold of medically unexplained pain symptoms by C. Froehlich; F. Jacobi; H.U. Wittchen (S552).
P.8.a.036 Effective pain reduction of non-pharmacological interventions for procedural pain during repetitive immunizations of children born pre-term by G. Petrilli; J.M.C. Blom (S553).
P.8.a.037 The Verona brain imaging study in schizophrenia: an integrated project with epidemiology and social psychiatry by N. Dusi; M. Tansella; A. Versace; N. Andreone; G. Rambaldelli; C. Perlini; C. Barbui; M. Nosè; D. Cristofalo; A. Gasparini; R. Cerini; P. Brambilla (S553-S554).
P.8.a.038 Sedative/hypnotic use and trends among United States elderly by D.A. Sclar; T.L. Skaer; L.M. Robison (S554).
P.8.a.033 Case-report of right unilateral anterior capsulotomy for obsessive-compulsive disorder by G. Degraeve; K. Audenaert; D. Van Den Abbeele; C. Van Heeringen; J. Caemaert; D. Van Roost (S551-S552).
P.8.a.032 Effects on sleep of caffeine and its combination with trazodone or zolpidem in healthy volunteers by L. Paterson; M. Ivarsson; P. Hutson; D.J. Nutt; S.J. Wilson (S551).
P.8.a.028 The role of gender in mixed mania: testing different definitions for mixed manic states by A. Aldama; F. Mosquera; C. González; S. Ron; J.R. Peciña; S. Aspiazu; A. González-Pinto (S548-S549).
P.8.a.026 Double blind trial of amantadine and haloperidol for treatment of delirium by Y.R. Kim; H.Y. Jung; I.S.Y. Lee; Y.J. Kwon; S.H. Cho; J.H. Hong (S548).
P.8.a.029 Obesity and eating disorders: analogies and differences by A. Goracci; G. Capano; I. Soreca; E. Cigna; C. Ciuoli; A. Di Muro; P. Castrogiovanni; F. Pacini (S549).
P.8.a.030 Validation of a translational model of insomnia in rats and human volunteers by L. Paterson; M. Ivarsson; P. Hutson; D.J. Nutt; S.J. Wilson (S550).
P.8.a.031 Anxiety, family support and alexithymia in patients with bronchial asthma by A. Tselebis; A. Karkanias; D. Bratis; K. Giotakis; G. Moussas; I. Ilias; K. Vassila-Demi (S550).
P.8.a.039 Driving ability in adults with attention-deficit hyperactivity disorder significantly improves when treated with methylphenidate by J.C. Verster; E.M. Bekker; M. De Roos; A. Minova; E.J.E. Eijken; U.S. Kooij; J.K. Buitelaar; J.L. Kenemans; M.N. Verbaten; B. Olivier; E.R. Volkerts (S554-S555).
P.8.a.040 A development and standardization of the Korean version Millon behavioural medicine diagnostics by K.Y. Lim; S.M. Cho; J.H. Kim (S555).
P.8.a.048 Childhood physical and sexual abuse in 100 nonviolent suicide attempters in Budapest by A. Rihmer; S. Rózsa; Z. Rihmer (S559-S560).
P.8.a.047 Searching susceptibility loci for maniacal and depressive polarities in bipolar disorders: a sib pairs study on chromosome 12 by C. Lorenzi; A. Pirovano; D. Dotoli; F. Bongiorno; E. Marino; M. Catalano; E. Smeraldi (S559).
P.8.a.049 Assessment of cortical lobe perfusion in schizophrenia: a magnetic resonance imaging study by M. Bellani; M. Tansella; C. Perlini; R. Cerini; G. Rambaldelli; M. Balestrieri; P. Brambilla (S560).
P.8.a.050 Gender differences in mood spectrum: clinical aspects by M. Carlini; L. Bevilacqua; P. Rucci; A. Baldini; C. Carmassi; F. Golia; L. Dell'Osso (S560-S561).
P.8.a.051 Attachment styles in patients with mood and anxiety disorders by A. Del Debbio; F. Mungai; L. Vivarelli; B. Dell'Osso; C. Carmassi; M. Carlini; D. Marazziti (S561).
P.8.a.046 Are zolpidem-induced amnesia and somnambulism rare incidences? by C.C. Chen; P. Yang; W.L. Chung; W.Y. Chour (S558-S559).
P.8.a.045 Subclinical hypothyroidism: psychopathological and cognitive aspects, quality of life and metabolic parameters before and after replacement with levothyroxine by M. Baldini; L. Airaghi; A. Orsatti; H. Aabid; A. Colasanti; M.A. Brambilla; M.C. Mauri (S558).
P.8.a.041 The correlation of dream recall and clinical variables in narcoleptics by S.P. Lee; J.H. Jeong; S.H. Hong; J.H. Han (S555-S556).
P.8.a.042 Persistent executive deficit in euthymic bipolar outpatients: a 2-year follow-up study by M. Mur; M.J. Portella; A. Martinez-Aran; J. Pifarre; E. Vieta (S556-S557).
P.8.a.043 Suggestion for safer prescription from the investigation on psychotropic drugs of suicide attempters by D. Kato; C. Kawanishi; T. Yamada; H. Hasegawa; R. Sato; I. Kishida; T. Furuno; Y. Hirayasu (S557).
P.8.a.044 Neuropsychological functioning in stabilised patients after a first psychotic episode by A. Jimenez; C. Gonzalez Gomez; A. Palomino; M.G. Dominguez; P. Vega; R. Gonzalez Oliveros; A. González-Pinto (S557-S558).
C.03.03 Monitoring patients to improve physical health and treatment outcome by P. Llorca (S573-S574).
C.03.04 Do we need another atypical antipsychotic? by S. Kasper (S574).
C.16.02 Cape Town consensus statement on OC spectrum disorders by D.J. Stein (S586).
C.16.01 Anxiety spectrum disorders over life cycle by E. Hollander (S585-S586).
C.16.03 The importance of serotonin (5-HT) and noradrenaline (NA) in anxiety by P. Blier (S586).
C.16.04 New treatment options for OCD by N. Fineberg (S586).
C.17.01 Lithium in mania: from John Cade to New Deli Study by J. Rybakowski (S587).
C.15.04 Depression and associated sleep disturbances: patient benefits with agomelatine by D. Kupfer (S585).
C.15.03 Major depressive disorders: clinical efficacy and tolerability of a new melatonergic antidepressant by S. Montgomery (S585).
C.14.02 The stable patient - from effectiveness to compliance by P. Thomas (S583).
C.14.01 The acute patient - efficacy without sedation by F. Cañas (S583).
C.14.03 The long-term - maximising potential for rehabilitation by A. Fagiolini (S584).
C.15.01 Treating depression today: clinical reality in using antidepressants by S. Kennedy (S584).
C.15.02 Pharmacological profile of antidepressants: a likely basis for their efficacy and side effects? by M. Hamon (S584-S585).
C.17.02 Valproate in mania: from Pierre Lambert to New Deli Study by C. Bowden (S587).
C.17.03 Comparison of lithium and valproate in the treatment of mania: efficacy issues by E. Vieta (S587-S588).
C.19.03 Long-term treatment of bipolar disorder: improving outcomes by W. Nolen (S590).
C.19.02 The increasing medical burden in bipolar disorder by E. Frank (S590).
C.20.01 The problem of depression and comorbid somatic and physical symptoms by D. Iosifescu (S590-S591).
Keyword Index (S611-S617).
C.19.01 Treatment adherence and long-term outcomes of bipolar disorder by M. Thase (S589-S590).
C.18.04 Measuring and monitoring patient outcomes -achieving positive outcomes with negative symptoms by N.R. Schooler (S589).
C.17.04 Comparison of lithium and valproate in the treatment of mania: predictive factors and tolerance issues by H. Grunze (S588).
C.18.01 The importance of recognising negative symptoms by Y. Lecrubier (S588).
C.18.02 Negative symptoms and brain imaging - the role of psychosis circuits by P. Boyer (S588-S589).
C.18.03 Current therapeutic options for negative symptoms by H.J. Möller (S589).
C.13.04 Stress paradigms enable genetic polymorphisms to manifest their effects by J. Den Boer; M. Jabbi (S583).
C.13.03 How do antidepressants regulate cortisol function? by C. Pariante (S582-S583).
C.07.02 Neurocognitive efficacy in patients with chronic schizophrenia by R. Keefe (S577).
C.06.04 Pharmacological treatment of adult ADHD by J.K. Buitelaar (S576-S577).
C.07.03 Schizophrenia as a progressive brain disorder by R. Kahn (S577).
C.08.01 Atypical antipsychotics: the pharmacological basis for their clinical effect by S. Stahl (S577-S578).
C.08.02 Treating bipolar disorder and comorbid conditions: current status and new directions by G. Goodwin (S578).
C.06.03 Non-pharmacological treatment of adult ADHD by T. Brown (S576).
C.06.01 Epidemiology and screening of adult ADHD in the general population and practice by R. Kessler (S576).
C.04.02 Managing comorbid anxiety with depression using currently available treatment options by P. Roy-Byrne (S574-S575).
C.04.01 Issues and challenges around anxiety and depression: co-conspirators for chronicity by M. Pollack (S574).
C.05.01 Links between pain and depression by M. Ackenheil (S575).
C.05.02 Antidepressants in pain by P. Delgado (S575).
C.05.03 SNRIs in the treatment of fibromyalgia syndrome by R. Gendreau (S575-S576).
C.08.03 Major depressive disorder (MOD) and bipolar depression: different diagnoses, same treatment? by G. Sachs (S578).
C.10.01 Generalized anxiety disorder (GAD): the treatment implications of clinical heterogeneity by B. Bandelow (S579).
C.12.02 Is depression neurodegenerative? by T.E. Schläpfer (S581).
C.12.01 Current controversies in depression treatment: a hot topics panel by J.E. Alpert; M. Detke; Y. Lecrubier; T.E. Schläpfer (S581).
C.12.03 Taking remission to the next level by J.E. Alpert (S581-S582).
C.13.01 Investigations into the genetic basis of mood disorders: What strategies can be used to identify candidate genes? by D. Blackwood (S582).
C.13.02 Preclinical models of stress, do they provide a basis for effective translation to the clinic? by H. Marston (S582).
C.11.04 Can we aspire to better outcomes for our patients? by P. Gorwood (S581).
C.11.03 Why do medications fail? by S. Keith (S580-S581).
C.10.02 Generalised anxiety disorder: differential efficacy of anxiolytic treatments across the range of symptoms and clinical subgroups by J. Boulenger (S579).
C.10.03 Neglected targets and future directions in the treatment of generalised anxiety by T. Dinan (S579-S580).
C.11.01 Factors contributing to treatment success by D. Naber (S580).
P.8.a.025 Testosterone levels in young male patients with affective disorder and schizophrenia by A. Rajewska-Rager; J. Rajewska; K. Kaminska; J. Rybakowski (S547-S548).
P.8.a.024 Evidence of efficacy for tc-1734 (azd3480) in the treatment of cognitive impairment in older subjects by G.C. Dunbar; R. Kuchibhatla; J.K. Wamsley (S547).
P.6.d.004 Brain imaging study on the effects of delta-9 THC on orientation and motor coordination in regular users of marijuana by A. Weinstein; O. Brickner; H. Lerman; M. Greemland; M. Bloch; R. Mechoulam; H. Lester; R. Bar Hamburger; R. Chisin; E. Even-Sapir (S509).
P.6.d.003 A morphometric evaluation of rat foetal cerebrum after maternal administration of morphine sulfate by S.H. Sadraie; G. Kaka (S508-S509).
P.6.d.005 mGlu1 receptor blockade attenuates cue- and nicotine-induced reinstatement of extinguished nicotine self-administration behaviour in rats by O. Dravolina; E.S. Zakharova; E.V. Shekunova; E.E. Zvartau; W. Danysz; A.Y. Bespalov (S509-S510).
P.6.d.006 Effects of dopamine and opioid receptor ligands on extinction of intravenous cocaine self-administration in drug naive mice by E. Blokhina; E.E. Zvartau; A.Y. Bespalov (S510).
P.6.d.007 Evaluation of the role of 5-HT1A receptors in dorsal and median raphe nuclei on the morphine withdrawal syndrome in rat by M. Charkhpour; A.M. Nayebi (S510-S511).
P.6.d.002 1-Methyl-1,2,3,4-tetrahydroisoquinoline, an endogenous neuroprotectant substance inhibits self-administration of cocaine: neurochemical correlates by L. Antkiewicz-Michaluk; J. Michaluk; M. Filip; I. Romańska (S508).
P.6.d.001 Ascorbic acid attenuates naloxone-induced withdrawal signs in morphine-dependent guinea-pigs by D. Farzin (S507-S508).
P.6.c.009 Benzodiazepine dependence disorder in a detoxification unit-aprospective study from 1993 to 2003 by N. Espluga Frigola; M.A. Malagon Amor; M.F. Fonseca Casals; C. Garnier Lacueva; G. Mateu Codina; M. Torrens Melich (S505).
P.6.c.008 One year retention rates and outcomes methadone and buprenorphine maintenance treatments: a nationwide prospective-longitudinal study of 2694 patients by H.U. Wittchen; S.M. Apelt; M. Soyka; M. Gastpar; M. Backmund; J. Goelz; M. Kraus; F. Tretter; M. Schaefer; J. Siegert; A. Guenther; J. Rehm; G. Buehringer (S504-S505).
P.6.c.010 The effects of cannabinoids in man: a systematic review of neuroimaging studies by A.B. Fagundo; R. Martín-Santos; J.A. Crippa; M. Seal; Z. Atakan; P. McGuire (S505-S506).
P.6.c.011 Pathological gambling:treatment correlates by A.V. Ravindran; J. Telner; R. Bhatla; C. Cameron; E. Horn; D. Horner; L. Cebulski; S. Davies (S506).
P.6.c.012 Differential traits in cannabis use disorder patients in a detoxification unit by G. Mateu; D. Berge; F. Fonseca; M. Torrens (S507).
P.6.d.008 Calcium channel antagonists attenuate amphetamine-and nicotine-induced anxiety-related responses in mice by G. Biala; M. Kruk (S511).
P.6.d.009 Blockade of morphine-induced behavioural sensitization by the association amisulpride-RB101 - comparison with classical opioid maintenance treatments by L. Cordonnier; M. Sanchez; B.P. Roques; F. Noble (S512).
P.6.d.017 Up-regulation of dopamine D3 receptor expression following continuous infusion of nicotine by M. Mugnaini; C. Corti; S. Mion; C.A. Heidbreder; M. Tessari (S516).
P.6.d.016 Changes in expression of G protein alpha subunits' mRNAs in rat amygdala after cocaine self-administration, withdrawal and the drug-or cue-induced reinstatement by I. Nalepa; A. Zelek-Molik; M. Filip; A. Wnuk; K. Wydra; J. Vetulani (S515).
P.6.d.018 New group of positive modulators of AMPA-receptors with cognition enhancing properties by V.V. Grigoriev; M. Lavrov; V.A. Palyulin; N.S. Zefirov; B.K. Besnosko; S.O. Bachurin (S516-S517).
P.6.d.019 Differential involvement of corticosterone and ghrelin on extinction of cocaine self administration and on cocaine-associated cue-induced reinstatement in rats by M. Tessari; A. Catalano; M. Pellitteri; F. Marini; C. Righetti; C. Di Francesco; P.A. Gerrard; C.A. Heidbreder; S. Melotto (S517).
P.6.d.020 CB1 cannabinoid and m opioid receptors density and functionality are altered in rats self-administering either heroin or the CB1 receptor agonist WIN 55,212 -2 by L. Fattore; D. Viganò; P. Fadda; T. Rubino; D. Parolaro; W. Fratta (S517-S518).
P.6.d.015 MDMA self-administration is abolished in serotonin transporter knockout mice by J.M. Trigo Díaz; T. Renoir; L. Lanfumey; M. Hamon; P. Robledo; R. Maldonado (S514-S515).
P.6.d.014 Intrahippocampal inhibition of protein kinase A attenuates morphine-induced conditioned place preference by M. Sharifzadeh; P. Tahsili-Fahadan; A. Haghighat; A.R. Zamanian (S514).
P.6.d.010 Adverse effects of maternal pre-mating opiate exposure on anxiety-related behaviour and nociception in the offspring by I.Y. Shamakina; V.A. Dubynin; A.A. Kamensky; Y.V. Dobryakova (S512).
P.6.d.011 Gender differences in effects of MDMA, cannabinoid agonist and their combinations in mice by J. Kucerova; L. Landa; K. Slais; A.E. Sulcova (S512-S513).
P.6.d.012 MDMA pre-treatment cross-sensitizes to methamphetamine stimulatory effects in mice by J. Kucerova; L. Landa; K. Slais; A.E. Sulcova (S513).
P.6.d.013 GABA(B) receptor agonists and a positive modulator reduce the “depressive-like” behaviours in rats during cocaine abstinence by M. Filip; M. Frankowska; A. Golda; M. Zaniewska; E. Przegalinski (S513-S514).
P.6.c.007 Pathways into ecstasy use: the role of prior cannabis use and ecstasy availability by H.U. Wittchen; P. Zimmermann; F. Waszak; A. Nocon; M. Hoefler; R. Lieb (S504).
P.6.c.006 The treatment of heroin withdrawal with dextromethorphan in Han Chinese: a randomized double-blind placebo-controlled trial by W.W. Lin; P.L. Tao; J.F. Lee; R.B. Lu; H.C. Ko (S503-S504).
P.6.a.012 Alcohol detoxification improves depressive symptomatology by J.A. Liappas; E.O. Tzavellas; T.J. Paparrigopoulos; C.R. Soldatos (S495).
P.6.a.011 Childhood adversity associated with reduced central dopamine sensitivity later in life, a pre-morbid vulnerability to develop alcohol dependence? by A.F.A. Schellekens; A. Ellenbroek; C.A.J. De Jong; J.K. Buitelaar; R.J. Verkes (S494-S495).
P.6.a.013 Sleep problems in alcohol dependence by T.J. Paparrigopoulos; E.O. Tzavellas; J.A. Liappas; C.R. Soldatos (S495-S496).
P.6.a.014 Effects of pharmacological anti-craving treatment in alcoholism on stress axis activity by F. Kiefer; H. Jahn; K. Wiedemann (S496).
P.6.a.015 Cognitive topography imbalance in alcoholism and psychiatric comorbidity by P. Papart; F. Liota; F. Bartholomé; M. Ansseau (S496).
P.6.a.010 Students' blood alcohol concentration and bicycle accident risk after an evening of alcohol consumption by J.C. Verster; J. Van Herwijnen; B. Olivier; E.R. Volkerts (S494).
P.6.a.009 Clinical signi .cation of pathological impulsivity in abstinent alcohol-dependent patients by M. Jimenez; M. Iribarren; R. Rodriguez; G. Rubio (S493).
P.6.a.005 The role of dopamine 2 receptor gene and personality characteristics in alcohol dependence in Turkish population by A. Kitis; Y. Akvardar; C. Eresen; S. Kizildag; U. Akpulat; S. Yildirimcan; K. Alptekin; B.B. Akdede; H. Arkar (S491).
P.6.a.003 Oxcarbazepine in alcohol relapse prevention - a randomized open trial by B. Croissant; A. Diehl; O. Klein; H. Nakovics; A. Heinz; K. Mann (S491).
P.6.a.006 Temperament differences between early and late onset male alcoholic patients by S.W. Lim; K.S. Oh; Y.C. Shin; J.W. Paik; H.J. Lee; J.G. Kim; S.J. Yang; H.T. Kim; S.B. Paik; Y.H. Jin (S492).
P.6.a.007 Risks and pattern of alcohol withdrawal delirium by B. Maneeton; N. Burapakajornpong; M. Srisurapanont (S492-S493).
P.6.a.008 Emotional awareness deficits in patients with alcohol dependence by J.J. Lee; U.S. Chung; Y.T. Kim; D.H. Kwon (S493).
P.6.b.001 The endocannabinoid system in the effects of alcohol on limbic neurons:an in vivo electrophysiological study by M. Pistis; S. Perra; G. Pillolla; A.L. Muntoni; M. Melis (S496-S497).
P.6.b.002 Genetic polymorphism of alcohol metabolizing enzymes, CYP2E1, in Korean male and female alcoholics by S.G. Kim; C.J. Kang; J.H. Park; W.T. Byun; I.B. Hwang (S497).
P.6.c.002 Attention deficits in schizophrenic patients with comorbid substance abuse by K. Krysta; A. Klasik; I. Krupka-Matuszczyk; M. Sygut; L. Hubicki (S501).
P.6.c.001 Benzodiazepines misuse in outpatients treated by internists by M. Srisurapanont; S. Suttajit; P. Lerttrakarnnon (S500-S501).
P.6.c.003 Methadone dose level influence on the efficiency of the treatment by L. Ignjatova (S502).
P.6.c.004 Are benzodiazepine expenses judiciously invested? by J. Irurita; M. Irurita; C. Deniz; M.T. Martinez Saavedra; C. Culebras; M.S. Rodriguez; B. Ania; J.M. Saavedra; R. Chirino; F. Sanchez (S502-S503).
P.6.c.005 Meta-analyses of opiate maintenance therapies by M. Ansseau; J. Reggers; L. Somers; F. Richy; P. Van Deun; B. Sabbe (S503).
P.6.b.008 Modulation of gabaergic transmission in alcoholic subjects and sons of alcoholics by T.F. Dielentheis; M. Schreckenberger; C. Landvogt; K. Hobusch; J. Hirsch; K. Mann; P. Bartenstein; G. Gründer (S500).
P.6.b.007 Is there an association between nicotine dependence and compulsive alcohol craving? by T. Hillemacher; K. Bayerlein; J. Wilhelm; H. Frieling; S. Bleich (S500).
P.6.b.003 Dopamine-related gene polymorphisms and alcohol withdrawal symptoms in patients with alcohol dependence by B. Kee; Y.S. Lee; K.J. Min; K. Paik; D. Park (S498).
P.6.b.004 Effect of amino acid derivatives and lipoic acid on lipid peroxidation and antioxidant systems indices in the rat brain during alcohol withdrawal by P.S. Pronko; T.I. Khomich; L.R. Bardina; V.I. Satanovskaya; O.A. Borodich (S498-S499).
P.6.b.005 Effects of olanzapine on ethanol withdrawal syndrome in rats by N. Unsalan; H. Kayir; E. Saglam; I.T. Uzbay (S499).
P.6.b.006 The role of epigenetic HERP dysregulation in patients with alcohol dependence by S. Bleich; B. Lenz; D. Bönsch; H. Frieling (S499-S500).
P.6.d.021 Histo-and immunochemical detection of inducible NOS and TNF-alpha in the locus coeruleus of human opiate addicts by I.V. Dyuizen; N.E. Lamash (S518).
P.6.d.022 Behavioural responses induced by nicotine in delta-opioid receptor knockout mice by F. Berrendero; L. Galeote; A. Bura; B.L. Kieffer; R. Maldonado (S518-S519).
P.8.a.007 Association between individual differences in slow wave sleep, slow wave activity and sleep continuity in young, middle-aged and older men and women by D.J. Dijk; J. Groeger; S. Deacon; N. Stanley (S538).
P.8.a.006 Can treatment of depression in primary care be improved with group counselling and patient education? by M. Hansson; O. Bodlund (S537-S538).
P.8.a.008 The utility of structural neuroimaging in the psychiatric inpatients by M.P.G. Pérez; Y.P.R. Prado; M.P.F. Páramo (S538-S539).
P.8.a.009 Hyponatremia during psychopharmacological treatment - results of a drug surveillance program by M. Letmaier; A. Konstantinidis; C. Egger; R. Grohmann; S. Kasper (S539).
P.8.a.010 Effects of galantamine on serum vitamin B12 and folic acid levels in patients with chronic fatigue immune dysfunction syndrome by A. Asdemir; S. Ozsoy; H.B. Izgi; M. Kula; M. Deveci; B. Yildiz; T. Turan; E. Esel; M. Basturk; M. Kirnap; S. Sofuoglu (S539-S540).
P.8.a.005 Familial heritability of increased homocysteine in schizophrenia by V. Geller; J. Levine; Y. Bersudsky; R.H. Belmaker (S537).
P.8.a.004 Nocturnal eating episodes after taking zolpidem: are they sleep problems or eating problems? by J.M. Kim; Y.C. Kim; H.B. Shin; W.J. Lim; K.W. Yun; K.W. Paik (S536-S537).
P.7.e.002 Concentrations and glycosylations profile of acute phase proteins in anorexia nervosa by R. Komorowska-Pietrzykowska; A. Rajewski; M. Sobieska; K. Wiktorowicz (S534-S535).
P.7.e.001 Serum concentrations of interleukin 4 and interleukin 10 in patients suffering from anorexia nervosa by R. Komorowska-Pietrzykowska; A. Rajewski; M. Sobieska; K. Wiktorowicz (S534).
P.8.a.001 The role of cytokine network in the pathophysiology of suicidal depression by Y.K. Kim; S.J. Kim (S535).
P.8.a.002 Quality of life in vitiligo and chronic urticaria patients by M. Sukan; F. Maner (S535-S536).
P.8.a.003 Huber basic symptoms (HBS) and eating disorders (ED) by P. Lorenzi; E. Angeli (S536).
P.8.a.011 Effects of galantamine on serum progesterone and DHEAS levels in female patients with chronic fatigue immune dysfunction syndrome by H.B. Izgi; A. Asdemir; F. Tanriverdi; S. Ozsoy; E. Esel; T. Turan; M. Basturk; B. Yildiz; Z. Candan; F. Kelestimur; S. Sofuoglu (S540).
P.8.a.012 Subtle cognitive impairments in siblings of male adolescents with non-psychotic psychiatric disorders by M. Weiser; A. Reichenberg; E. Kravitz; G. Lubin; M. Shmushkevitz; S. Noy; M. Davidson (S541).
P.8.a.020 Dopaminergic, noradrenergic, adrenal and thyroid abnormalities in schizoaffective disorder by F. Duval; M.C. Mokrani; J.A. Monreal Ortiz; C. Champeval; N. Chokmani; J.P. Macher (S545).
P.8.a.019 Seasonally of cortisol secretion by A.L. Morera; P. Abreu; M. Henry; A. Garcia-Hernandez; F. Guillen-Pino; R. Gracia (S544-S545).
P.8.a.021 Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with ADHD by J. Biederman; T.J. Spencer; E. Mick (S545-S546).
P.8.a.022 Analysis of the hospitalized frustrated suicides, classified according to the violence of the method used by C. Castro Dono; F. Iglesias Gil de Bernabé; J. García Fernández; M. Filgueira Bouza; E. Fontela Vivanco; S. Segade Rodríguez; S. González Bardanca; J. Alberdi Sudupe; L. Ferrer i Balsebre; M. Amboage Paz (S546).
P.8.a.023 Lifetime comorbidity in bipolar disorder: bipolar subtype and gender differences by B. Grabski; D. Dudek; W. Datka; G. Maczka; A. Zieba (S546-S547).
P.8.a.018 Use of psychotropic drugs in older people with mental illness by S. Curran; S. Musa; D. Turner (S544).
P.8.a.017 A flexible dose open label trial evaluating the efficacy and safety of quetiapine as adjunctive pharmacotherapy for the treatment of generalized anxiety disorder (GAD) by M.A. Katzman; M. Vermani; L. Jacobs; M. Marcus; S. Lessard; W. Galarraga; B.Y. Kong; L. Struzik; A. Gendron (S543).
P.8.a.013 Personality disorders in a sample of schizophrenic patients by M. Henry; A.L. Morera; A. Garcia; L. Fernandez; I. Fernandez; R. Gracia (S541).
P.8.a.014 Long-term evolution follow-up of patients treated with electroconvulsive therapy by M.T.A. Tajes; S.M.F. Martínez; M.P.F. Páramo (S541-S542).
P.8.a.015 EEC-sleep profiles, hypothalamic-pituitary-adrenocortical (HPA) activity, and association with psychological/behavioural variables in pre-schoolers by M. Hatzinger; S. Brand; S. Perren; S. Stadelmann; A. von Wyl; K. von Klitzing; E. Holsboer-Trachsler (S542).
P.8.a.016 Impact of cerebrovascular accident on medical service resource utilization in a regional hospital by A. Sicras Mainar; R. Navarro Artieda; M. Blanca Tamayo; J.R. Llopart Lopez; J. Serrat Tarres; J. Rejas Gutierrez (S542-S543).
P.7.d.004 A preliminary study for standardization of the PSQ-K (paediatric sleep questionnaire -Korean version) in Korean children by Y.S. Kweon; W.H. Jeun; J.H. Lee; H.K. Lee; K.U. Lee; J.T. Lee (S533-S534).
P.7.d.003 The validity of the quality of life enjoyment and satisfaction questionnaire in adults with ADHD by E. Mick; J. Biederman; T. Spencer; S.V. Faraone; H. Zhang (S533).
P.7.a.001 Obsessive-Compulsive syndrome in adolescent schizophrenia by M. Hrdlicka; P. Kollarova; I. Dudova (S523).
P.6.f.003 Effects of neonatal serotonin depletion on reinforcing and rewarding properties of cocaine in rats by R. Stefanski; P. Krzascik; P. Kolomanska; P. Rock; E. Wyszogrodzka; W. Kostowski (S522-S523).
P.7.a.002 Use of levetiracetam in Asperger's Disorder patients: an open-label trial by A.W. Mech (S523-S524).
P.7.a.003 Divalproex sodium for the treatment of irritability in autism by E. Anagnostou; W. Chaplin; J. Rusoff; L. Soorya; E. Hollander (S524).
P.7.a.004 The difference of IQ and behavioural problems among ADHD children showing modality-specific attention problem by J.W. Son; S.I. Lee; S.K. Kim; C.J. Shin (S524-S525).
P.6.f.002 Behavioural sensitization to nicotine in drug discrimination procedure by H. Kayir; U. Yazgan; O. Yavuz; B. Acikmese; I.T. Uzbay (S522).
P.6.f.001 Is drive satisfaction mechanism (“antidrive”) involved in substance addiction? by W. Kostowski; J. Beck (S521-S522).
P.6.d.024 C385A FAAH SNP is related to substance use disorder but not to schizophrenia in a Spanish sample by I. Martínez-Gras; G. Ponce; R. Rodriguez-Jimenez; G. Rubio (S519-S520).
P.6.d.023 Differential potencies of Ecstasy derivatives in [3H] 5-HT uptake and evoked release from rat hippocampal slices by F.D. Pasquier; A. Felim; A. Neudörffer; F.P. Monnet (S519).
P.6.e.001 State and trait anxiety, smoking and gender by D. Zullino; E. Fresard; Y. Khazaal; A. Chatton; J.G. Bavarel; Y.A. Kaufmann; D. Benguettat; R. Khan; R. Annoni Manghi (S520).
P.6.e.002 Efficacy of sertraline in the treatment of alcohol dependence by V.L. Lazarova; M.J.K. Jakovcevska Kujundziska; V.F. Filovska; R.K. Krstevska (S520-S521).
P.6.e.003 Alprazolam-induced changes in cognitive and psychomotor performance in subjects with a history of recreational sedative-hypnotic drug use by S.L. McColl; R. Schuller; B. Danilov; M.K. Romach; E.M. Sellers; M. Grigorova (S521).
P.7.b.001 Prefrontal N-acetyl-aspartate and cognition in adolescents with first-episode psychosis by A. Zabala; J. Sánchez; O. Robles; D. Moreno; M.T. Burdalo; M.J. Parellada; P. Laita; M. Desco; C. Arango (S525-S526).
P.7.b.002 Association of DAO and DAOA genes with autism spectrum disorders in Korean boys by J.W.J. Jeon; S.H.C. Chung; J.P.H. Hong; H.I.Y. Yoo (S526).
P.7.c.008 The clinical characteristics of the adolescent attention deficit/hyperactivity disorder (ADHD) patients and treatment effects of an extended-release preparation of methylphenidate (more large sample size than previous study) by E.Y. Oh (S530-S531).
P.7.c.007 Comparison of treatment of disruptive behaviour disorders in children and adolescents with quetiapine and risperidone by M.Z. Hussain; W. Waheed; S. Hussain (S530).
P.7.c.009 Effects of methylphenidate on leptin and appetite in children with attention deficit hyperactivity disorder by E. Ýseri; E.G. Kilic; S. Senol; N. Ilgin Karabacak (S531).
P.7.d.001 Functional MRI of response inhibition in autism by E. Anagnostou; J. Fan; E. Hollander (S531-S532).
P.7.d.002 Darkness-induced alertness-increase in children with attention deficit hyperactivity disorder and its diminution by methylphenidate by Z. Tokaji; K. Szabó; K. Nagyova; À. Vetró (S532).
P.7.c.006 Antipsychotic drugs in children and adolescents: QTc interval elongation by P. Laita; C. Franco; C. Llorente; A. Cifuentes; A. Ulloa; D. Fraguas; C. Arango (S529-S530).
P.7.c.005 Pharmacokinetics, detection, likeability and dislikeability of two formulations of long-acting oral methylphenidate by T.J. Spencer; J. Biederman; P. Ciccone; B. Madras; D.A. Parasrampuria; A.J. Fischman; E. Mick; J. Martin; T. McDonnel (S529).
P.7.c.001 Akathisia as frequent side effect of anaesthesia with neuroleptics in patients with attention deficit/hyperactivity disorder by J. Krause; K.H. Krause (S526-S527).
P.7.c.002 Risperidone versus haloperidol in the treatment of children with Tourette's syndrome and chronic motor or vocal tic disorder in Korea by L.K.Y. Lim; S.Y.M. Shin (S527).
P.7.c.003 Atomoxetine in the treatment of psychostimulant-naive children and adolescents with ADHD: a 6-week, randomized, placebo-controlled trial in Russia by F. Martenyi; N. Zavadenko; N. Jarkova (S527-S528).
P.7.c.004 Efficacy, tolerability and safety of the use of quetiapine combined with fluoxetine in patients with severe anorexia nervosa restrictive type by Z. Fernandez; M.J. Ductor; J.L. Galan; C. Martinez (S528).
P.3.a.013 Untreated patients with schizophrenia have a failure of inhibitory control systems during saccadic tasks by M.O. Krebs; M.C. Bourdel; H. Picard; S. Morel; S. Gray; P. Bouhours; H. Lôo; I. Amado (S371).
P.3.a.012 Low concentration of plasma nitric oxide metabolites in schizophrenic patients by B.H. Lee; Y.K. Kim; K.M. Lee (S370-S371).
P.1.a.014 Expressed gene differences on .uoxetine treatment in rat hippocampus by K.C. Paik; J.H. Choi; C.H. Han (S215-S216).
P.1.a.013 Antipsychotics-induced weight gain is associated with therapeutic response and the polymorphism of dopamine D3 receptor gene in Korean schizophrenia by H.C. Kim; S.W. Jung; D.K. Kim (S215).
P.1.a.015 Strain differences in susceptibility to unpredictable chronic mild stress as assessed by hippocampal gene expression profiling by J.L. Paya-Cano; F. Sluyter; Y.S. Mineur; C. Fernandes; W.E. Crusio; L.C. Schalkwyk (S216-S217).
P.1.a.016 Genetic and biological markers of families of patients with schizophrenia by L.A. Ryadovaya; E.V. Gutkevich; L.P. Pitina; L.A. Gorbacevich (S217).
P.1.b.001 Registration of multiunit activity and analysis of neuro-neuronal, cardio-neuronal and respiratory-neuronal temporal relationships by H. Prudnikau (S217-S218).
P.1.a.012 Transcripts expression profile of the genes assayed with the oligonucleotide microarray technique in young women with anorexia nervosa by K.M. Janas-Kozik; S.M. Stachowicz; K.M.I. Krupka-Matuszczyk; M.U. Mazurek (S214-S215).
P.1.a.011 Nature and nurture predispose to violent behaviour: on serotonergic genes and adverse childhood environment by A. Reif; M. Schneider; C.M. Freitag; P. Retz-Junginger; M. Rösler; C.P. Jacob; K.P. Lesch; W. Retz (S214).
P.1.a.007 Retinoid function related genes do not cause psychosis in a large inbred family by S. Ozer; B. Akýn; A. Uluşahin; N. Akarsu (S211-S212).
P.1.a.006 Manganese superoxide dismutase gene polymorphism in schizophrenics with tardive dyskinesia in Polish population by P. Gałcki; A. Florkowski; J. Szemraj (S211).
P.1.a.008 5-HTTLPR polymorphism of the serotonin transporter gene and history of suicide attempts in schizophrenic patients by B. Godlewska; L. Olajossy-Hilkesberger; J. Landowski (S212).
P.1.a.009 Methylenetetrahydrofolate reductase gene polymorphisms (C677T and A1298C) in patients with schizophrenia by C.C. Crisan (S213).
P.1.a.010 The C270T and Val66Met polymorphisms of brain-derived neurotrophic factor in schizophrenia by A. Juhász; Á. Rimanóczy; S. Kéri; C. Cimmer; G. Szekeres; I. Szendi; Z. Janka (S213-S214).
P.1.b.002 Anterior cingulate volumes in schizophrenia: a systematic research review and a meta-analysis of MRI studies by M. Baiano; A. David; A. Versace; R. Churchill; M. Balestrieri; P. Brambilla (S218).
P.1.b.003 Non-invasive measurement of vagus activity in the brainstem - a methodological progress towards earlier diagnosis of dementias? by A.J. Fallgatter; T. Polak; F. Metzger; M.M. Plichta; T. Ringel; A.C. Ehlis (S218-S219).
P.1.b.012 Relationship between kynurenines and S100b in CSF of schizophrenic patients by M.J. Schwarz; M. Riedel; S. Holdenrieder; S. Erning; M. Tischinger; N. Müller (S223).
P.1.b.011 The differences of electroencephalogram coherence between schizophrenia and bipolar disorder by J.W. Park; K.S. Hong; S.D. Park; Y.S. Lee (S222-S223).
P.1.b.013 Sleep assessments in patients with schizophrenia following treatment with paliperidone extended-release tablets by R. Luthringer (S224).
P.1.c.001 Assessment of cognitive impairment in patients with acute ischemic stroke in Menoufiya teaching hospital in Egypt by W. Yousef (S224).
P.1.c.002 Influence of nootropil on neuroplasticity of the brain cortex in conditions of hypokinesia by K. Melkonyan (S224-S225).
P.1.b.010 Low concentrations of plasma brain-derived neurotrophic factor in patients with panic disorder by J.C. Yang; Y.K. Kim; M.S. Lee; J.S. Yoon; S.J. Eun; H.Z. Cao (S222).
P.1.b.009 Neural stem cell proliferation is significantly reduced in schizophrenia, but not in affective psychoses by A. Reif; S. Fritzen; M. Finger; A. Strobel; A. Schmitt; K.P. Lesch (S221-S222).
P.1.b.005 Elevation of histamine H1 receptor mRNA level in hypothalamus of starved rats by H. Fukui (S219-S220).
P.1.b.004 Cortisol in stress response dampening in subjects at risk for alcoholism by B. Croissant; R. Olbrich; R. Demmel; F. Rist (S219).
P.1.b.006 Characterization of Gpr101 expression and G protein-coupling selectivity by M.H. Pausch; L. Zhang; S. Nawoschik; E. Tseng; K. Sreekumar; A. Kramer; Q. Shan; N. Taylor; J. Paulsen; B. Bates (S220).
P.1.b.007 Heart rate variability in patients with anxiety disorders by J. Dragasek; M. Drimalova; P. Durdik; M. Migra; G. Holla (S220-S221).
P.1.b.008 Distribution of glucocorticoid and mineralocorticoid receptors in the rat midbrain ventral tegmental area by G.O. Minton; S.E. Gartside (S221).
P.1.a.005 Association studies of the CT repeat polymorphism in the cholecystokinin B receptor gene with the diagnosis and the response of pharmacotherapy in Korean patients with panic disorder by W. Kim (S210-S211).
P.1.a.004 The association of promotor polymorphism in synapsin III gene with schizophrenia by L.C.H. Lee; P.J.H. Park; K.C.Y. Kim; H.O.S. Han; J.Y.H. Joo (S210).
S.27.01 Neurodevelopmental setpoint and vulnerability to disease by E. De Kloet (S202).
S.26.04 Do genes predict cognitive dysfunction in schizophrenia? by N. Andreasen; B.C. Ho; T. Wassink (S202).
S.27.02 Social isolation and brain function by C. Marsden; M. Bianchi; M.C. Pardon; V. Porkess; K.C.F. Fone (S202-S203).
S.27.03 Prenatal stress affects behaviour, neuroendocrine systems and hippocampal structure of primates in a persistent manner by E. Fuchs (S203).
S.28.01 Discovery and function of TPH2 by G. Vodjdani; C. Fligny; J. Mallet; F. Côté (S203).
S.26.03 Functional candidate genes derived from animal models and their impact in schizophrenia by D. Rujescu (S202).
S.26.01 Neurotransmitter genes in causation and treatment response by P. Gorwood; N. Hamdani; C. Dubertret; C. Boni (S201-S202).
S.25.02 Molecular genetics of smoking and co-morbid psychiatric disorders by M. Munafo (S200).
S.25.01 Epidemiology of smoking and co-morbid pychiatric disorders by P. Cuijpers; R. Van der Meer; M. Ten Have; R. De Graaf (S200).
S.25.03 Smoking cessation treatment in patients with depression: outcomes, relapse vulnerability factors, and targeted inventions by B. Hitsman (S200-S201).
S.25.04 Preliminary results from a RCT of a smoking cessation intervention for smokers with a history of major depression by G. Schippers; R. Van der Meer; M. Willemsen; P.H. Smit; P. Cuypers (S201).
S.25.05 Smoking cessation treatment in patients with schizophrenia: outcomes, relapse vulnerability factors, and targeted interventions by T.P. George; J.C. Vessicchio; A.H. Weinberger; K.A. Sacco (S201).
S.28.02 Influence of variants of TPH2 on the regulation of the central serotonin system by M.G. Caron; X. Zhang; J.M. Beaulieu; R.R. Gainetdinov; T. Sotnikova (S203-S204).
S.28.03 Gene-environment interaction: influence of serotonin on anxiety-like behaviour in mice by C. Gross; V. Carola (S204).
E.06.02 Gender differences: focus on anxiety and depression by D. Marazziti; L. Bevilacqua; M. Catena (S207).
E.06.01 Gender differences: focus on addiction by G. Fischer; N. Ebner; B. Winklbaur; K. Thau (S206-S207).
P.1.a.001 Serotonin 5-HT1B gene polymorphism (C129T) in homicidal schizophrenics by S.K. Wang; I.H. Jeong; I.S. Chee; Y.O. Shin; S.W. Lee (S209).
P.1.a.002 Protective effect of haplotype of dysbindin gene (DTNBP1) on chromosome 6p22.3 to major depressive disorder by J.J. Kim; C.U. Pae; T.S. Kim; C.U. Lee; S.J. Lee; C. Lee; T.Y. Jun; I.H. Paik (S209-S210).
P.1.a.003 The serotonin transporter gene: association with different psychiatric disorders by D. Gaysina; A. Zainullina; E. Jurjev; G. Faskhutdinova; T. Noskova; E. Khusnutdinova (S210).
E.05.02 Assessing the noradrenalin system in humans by D. Nutt (S206).
E.04.02 Treatment of adult ADHD by E. Taylor (S206).
S.28.04 TPH expression in human brain and its importance for psychiatric disorders by M. Ackenheil; B. Bondy; A. Buttner; P. Zill (S204).
E.02.01 Psychopharmaca in the management of the consequences of disasters by J.J. López-Ibor (S205).
E.02.02 Cognitive behavioural interventions for acute and chronic PTSD by E. Foa (S205).
E.04.01 Diagnosis and assessmentof adult ADHD by J.K. Buitelaar (S205-S206).
P.1.c.003 Appropriate intervention strategies in overweight induced by olanzapine: a randomized-controlled study by K. Giaquinto; W. Milano; C. Petrella; P. Renzi; A. Capasso (S225).
P.1.c.004 Different Salvia species as ligands for selected central nervous system receptors: in vitro binding experiments by F. Cavallo; C. Nencini; A. Capasso; G. Bruni; L. Micheli (S225-S226).
P.1.c.040 Long-lasting cognitive enhancing effects of S 18986, a positive modulator of AMPA receptors, in the object recognition task in rats by V. Bertaina-Anglade; K. Bernard; C. Munoz; P. Morain; C. Drieu la Rochelle (S245).
P.1.c.039 Effects of aripiprazole on dopamine and 5-HT function in rabbit brain by T. Kawamura (S244-S245).
P.1.c.041 Fluorescence in vitro studies of human adenosine A2A and serotonin 5HT1A receptors homodimerization by S. Lukasiewicz; E. Blasiak; A. Faron-Gorecka; Z. Wasylewski; M. Dziedzicka-Wasylewska (S245-S246).
P.1.c.042 Stress causes stressor-specific changes in extracellular levels of GABA in the hippocampus by A.C.E. Linthorst (S246).
P.1.c.043 The effects of risperidone, olanzapine and haloperidol on enzyme activities in kidney tissue of rats by M. Gulaboglu; Z. Halici; N. Aydin; E. Cadirci; M. Gul; H. Suleyman; E. Oral (S246-S247).
P.1.c.038 Effects of bupropion on extracellular dopamine concentrations in rat medial prefrontal cortex and nucleus accumbens studied by in vivo microdialysis by A. Kusaka; K. Kitazumi; K. Nakayama (S244).
P.1.c.037 Mitochondria as the memantine target by E.P. Shevtsova; L.G. Dubova; E.G. Kireeva; S.O. Bachurin (S243-S244).
P.1.c.033 Comparison of risperidone, olanzapine and quetiapine in relation to body weight, serum blood glucose and prolactin levels by H.R. Chaudhry; S. Niaz; N. Arshad; F. Peracha; A. Ayub; K.A. Mufti (S241).
P.1.c.032 Regulation of NA and GABA systems on DOI (agonist 5-HT2A/2C) anxiolytic-like effect in the four-plate test and cerebral localization of target receptors by F. Masse; M. Hascoet; M. Bourin (S240-S241).
P.1.c.034 Pharmacokinetics of licarbazepine in healthy volunteers: single and multiple oral doses and effect of food by C. Souppart; A. Gardin; G. Greig; S. Balez; Y. Batard; A. Krebs-Brown; S. Appel-Dingemanse (S242).
P.1.c.035 Gabapentin and topiramate protect rat neurons against staurosporine induced apoptosis by S. Abramovici; O. Bajenaru; B.O. Popescu (S242-S243).
P.1.c.036 Seizure-induced hypothermia in biotelemetered rats by E.S. Akarsu (S243).
P.1.c.044 Efficacy and mechanism of antidyskinetic activity of sarizotan by G.D. Bartoszyk; M. Gerlach; M. Van den Buuse; P. Riederer (S247).
P.1.c.045 The effects of risperidone, olanzapine and haloperidol on enzyme activities in erythrocytes and plasma of rats by Z. Halici; F. Ozabacigil; N. Aydin; M. Gulaboglu; M. Gul; H. Suleyman (S247-S248).
P.1.d.004 Effects of a selective and brain penetrating 5-HT6 receptor antagonist in animal models of depression and anxiety by A. Wesolowska; A. Nikiforuk; K. Stachowicz; E. Chojnacka-Wojcik (S251-S252).
P.1.d.003 The effects of prenatal hypoxia at the beginning of organogenesis on neuronal resistance to oxidative stress by A.V. Graf; M.V. Maslova; E.R. Buligina; N.A. Sokolova (S251).
P.1.d.005 Effect of environmental enrichment on behaviour of mice in plus-maze tests depends on length of exposure by P. Pokk; K. Õkva; A. Lang; M. Väli; T. Nevalainen (S252).
P.1.d.006 Behavioral phenotyping of sodium-myo-inositol cotransporter knockout mice with reduced brain inositol by Y. Bersudsky; A. Shaldubina; R. Johanson; R. Buccafusca; G. Agam; R.H. Belmaker; G. Berry (S252-S253).
P.1.d.007 NAN-190 facilites learning impairment induced by scopolamine in estradiol-treated ovariectomized rats by J. Fedotova; N. Sapronov; N. Losev (S253).
P.1.d.002 Aggressive and hyperactive behavioural characteristics is increased in maternal social separated rat by H.R. Kwak; J.I. Park; H.J. Ko; S.J. Kim; Y.S. Choi; H.J. Lee (S250-S251).
P.1.d.001 Assessment of the effects of milnacipran on rewarding properties of alcohol in rats by M. Naassila; M. Daoust; J. Molet; R. Dupont (S250).
P.1.c.046 The antidyskinetic drug sarizotan exhibits functional selectivity at D2-like dopamine receptors: relevance for its antidyskinetic mechanism of action by E.V. Kuzhikandathil; G.D. Bartoszyk (S248).
P.1.c.047 A double-blind, placebo-controlled investigation of the anxiolytic effects of XBD173 (AC-5216) and alprazolam using a CCK-4-induced panic challenge by R. Rupprecht; D. Eser; C. Schuele; K. Kucher; M. Merz; A. Krebs-Brown; A. Floesser; X. Lataste; I. Bruenig-Traebert; R. Zaninelli (S248-S249).
P.1.c.048 The involvement of the descending dopaminergic pathway in the systemic cannabinoids, but not opioid-induced antinociception by A. Dogrul; I.T. Uzbay (S249).
P.1.c.049 Descending serotonergic pathways play an inhibitory or facilitatory role in spinal pain processing by 5-HT7 or 5-HT3 receptors in acute and chronic pain by A. Dogrul; M. Ossipov; J. Lai; F. Porreca (S249-S250).
P.1.c.031 Effect of acute and chronic light/dark cycle alteration on seizure threshold in mice: modulation by melatonin by N. Yahyavi-Firouz-Abadi; P. Tahsili-Fahadan; K. Riazi; A.R. Dehpour (S240).
P.1.c.030 Antidepressant treatment reduces fos-like immunoreactivity in different regions of periaqueductal gray matter by R.M.W. Oliveira; C. Lino-de-Oliveira; A.P. Carobrez; T.C.M. De Lima; E.A. Del Bel; F.S. Guimãraes (S239-S240).
P.1.c.013 NMDA receptors of the central amygdala are involved in morphine-induced conditioned place preference by F. Golhasani-Keshtan; A. Rezayof; M.R. Zarrindast; A. Haeri Rohani; F. Nazari-serenjeh; L. Delphi (S230).
P.1.c.012 Anti-aversive effect of acute clomipramine and .uoxetine on fear-induced behaviour elicited by preys in confront with rattlesnakes by D.H. Elias-Filho; W.A. Ubiali; N.C. Coimbra (S229-S230).
P.1.c.014 The effect of an endogenous neuroprotective compound 1-methyl-1,2,3,4-tetrahydroisoquinoline on cocaine-induced locomotor sensitization and in vivo release of dopamine in rat striatum by A. Wasik; A. Patsenka; I. Romańska; L. Antkiewicz-Michaluk (S231).
P.1.c.015 The role of voltage dependent sodium channels on the antidepressant-like effect of lamotrigine by F.T. Codagnone; F.T. Consoni; A.L.S. Rodrigues; M.A.B. Vital; R. Andreatini (S231-S232).
P.1.c.016 New tranquilizers - prodrugs for slow and prolonged release by oral administration by I.A. Kravchenko; A.I. Sivko (S232).
P.1.c.011 Chronic treatment with paroxetine decreases defensive reactions elicited by golden hamsters in confront with venomous coral snakes by T. Paschoalin-Maurin; D.H. Elias-Filho; N.C. Coimbra (S229).
P.1.c.010 From selective to highly selective SSRIs: the antinociceptive properties of four serotonergic antidepressants by S. Schreiber; C.G. Pick (S228-S229).
P.1.c.006 Modification of formalin-induced nociception by different histamine receptor agonists and antagonists by D. Farzin; N. Mansouri (S226-S227).
P.1.c.005 Polymorphism of the serotonin transporter promoter may predict the response to selective serotonin reuptake inhibitors in bulimia nervosa by K. Giaquinto; A. Capasso; P. Monteleone; M. Maj (S226).
P.1.c.007 Anti-aversive effect of endogenous opioid peptides-receptors blockade on innate and conditioned fear elicited by preys submitted to an aggressive encounter with South American rattlesnakes by N.C. Coimbra; F. Calvo; I. Tracey (S227).
P.1.c.008 The effects of venlafaxine on neurites growth of PC12 cells by J.N. Lee; B.H. Yang (S227-S228).
P.1.c.009 Ethanol state-dependent learning: involvement of dopamine D2 receptors of dorsal hippocampus by A. Rezayof; T. Motevasseli; Y. Rassouli; M.R. Zarrindast; R. Amini (S228).
P.1.c.017 F15599, a highly selective serotonin 5-HT1A receptor agonist: in vitro affinity and efficacy profile at native rat and recombinant human 5-HT1A receptors by A. Newman-Tancredi; M.B. Assié; C. Cosi; L. Bruins Slot; D. Cussac; J.C. Martel (S232-S233).
P.1.c.018 F15599, a highly selective serotonin 5-HT1A receptor agonist: in vivo profile in neurochemical and behavioural models of serotonergic activity by M.B. Assié; L. Bardin; R. Depoortere; E. Carilla-Durand; A. Newman-Tancredi (S233).
P.1.c.026 a-1 Adrenergic receptors stimulation induces the proliferation of neural progenitor cells by T. Hiramoto; Y. Watanabe (S237-S238).
P.1.c.025 The activity of cytochrome P450 CYP2D in rat brain and the CYP2D2-mediated dopamine formation by W.A. Daniel; A. Haduch; E. Bromek (S237).
P.1.c.027 Comparative efficacy of liposome-entrapped amiloride and free amiloride in animal models of seizures and serum potassium in mice by A. Ali; K.K. Pillai; F.J. Ahmad; D. Vohora (S238-S239).
P.1.c.028 The administration of the cannabinoid CB1 receptor antagonist AM-251 blocked the anxiolytic and sedative actions of benzodiazepines by D.V. Navarro; E. Sanguino; J. Manzanares (S239).
P.1.c.029 A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on CYP 3A4 by A.H. Andreasen; K. Brøsen; P. Damkier (S239).
P.1.c.024 Effects of haloperidol on intracellular calcium ion change in hamster insulinoma cells by M.H. Kim; J.H. Shin; K.C. Park; G.S. Park; I.D. Gong; T.H. Kim (S236-S237).
P.1.c.023 Thioperamide, a selective histamine H3 receptor antagonist, reduces intracellular calcium in mouse brain synaptosomes by D. Vohora; S.N. Pal; K.K. Pillai (S236).
P.1.c.019 5-HT2A/2C receptors modulate behaviour and c-fos expression in ovariectomized rats in forced swim test by S. Barabanova; J. Fedotova; N. Platonova; N. Sapronov (S234).
P.1.c.020 Regulation of cytochrome P-450 activity by the brain dopaminergic system by J. Wójcikowski; K. Gołembiowska; W.A. Danie (S234-S235).
P.1.c.021 Monoamine oxidase B density is increased in the frontal cortex of suicide victims by L.F. Callado; J. Ballesteros; A.I. Maeztu; M. Gutierrez; J.J. Meana (S235).
P.1.c.022 Effects of prenatal exposure to nitric oxide synthase inhibitor on MK-801-elicited behavioural sensitivity in postnatal juvenile rats by S.H. Park; G.J. Kim; Y.I. Chung (S235-S236).
S.24.05 Gaboxadol, the .rst therapeutic agent to target extrasynaptic inhibition by B. Ebert (S199).
S.24.04 An overview of synaptic/extrasynaptic inhibition and its therapeutic potential by M.C. Walker (S199).
S.07.02 Prenatal stress in rats attenuates hippocampal long-term potentiation and induces deficits in synaptic plasticity by S. Salomon; H. Matzner; R. Yaka; M. Weinstock (S175).
S.07.01 The effect of lithium on various isoforms of adenylyl cyclase by L. Mann; G. Shaltiel; E. Heldman; R.H. Belmaker; G. Agam (S175).
S.07.03 RIC-3, an effector of nAChR activity: structure, function, quantity, and regulation by Y. Biala; M. Treinin (S175-S176).
S.07.04 Vagus nerve stimulation increases neurotrophins gene expression and alters cell proliferation in the rat hippocampus by P. Follesa; F. Biggio; G. Gorini; S. Caria; F. Marrosu; G. Biggio (S176).
S.07.05 Autism candidate genes in cytogenetic regions of interest identified with a gene interaction network by W. Staal; L. Franke; J.A.S. Vorstman; R. Hochstenbach; H. Van Engeland (S176).
S.06.03 Dopamine and OCD: preclinical and clinical evidence by D. Denys (S175).
S.06.02 Neurocognitive functioning in OCD: an endophenotype by N. Fineberg; S.R. Chamberlain; L. Menzies; A.D. Blackwell; E.T. Bullmore; T.W. Robbins; B.J. Sahakian (S174).
S.05.03 Treatment of bipolar depression by E. Vieta; M. Garcia-Amador (S173).
S.05.02 Melatonin receptor agonists in depressive disorders and their treatment by B. Guardiola-Lemaître (S173).
S.05.04 Steroid hormone treatments by O.M. Wolkowitz; V.I. Reus; E. Epel; S. Mellon (S173-S174).
S.05.05 Antipsychotics in unipolar depression by S. Kasper (S174).
S.06.01 OCD: a multidimensional approach by E. Hollander; A. Allen; L. Rossi; D. Simeon (S174).
S.07.06 Specific effects of ecstasy on memory: a new approach to investigate neurotoxic effects in poly-substance ecstasy users by G. Jager; M.M.L. De Win; R.S. Kahn; J.M. Van Ree; W. Van den Brink; N.F. Ramsey (S176-S177).
S.07.07 The pre-synaptic dopaminergic system before and after the onset of psychosis: initial results by O.D. Howes; A.J. Montgomery; M.C. Asselin; R.M. Murray; P.M. Grasby; P.K. McGuire (S177).
S.09.02 Suicidality in bipolar disorders by D. Souery; S. Linotte; M. Barreto; J. Mendlewicz (S180).
S.09.01 Bipolar spectrum disorder: relapse and remission by L. Judd (S179-S180).
S.09.03 Antipsychotics in bipolar disorders by H. Grunze; F. Seemüller; A. Forsthoff; C. Born (S180).
S.09.04 New antiepileptics in bipolar mixed states by G. Perugi (S180-S181).
S.10.01 Pathological gambling: an addiction phenotype? by J. Adès (S181).
S.08.05 New directions in the drug treatment of schizophrenia: metabotropic glutamate receptors by D. Schoepp (S179).
S.08.04 Dopamine D3 receptors as a target for the treatment of schizophrenia: contrasting actions of antipsychotic agents by M. Millan (S179).
S.07.08 Is controversial efficacy of SSRI in treating depression in child and adolescent related to differences in study design? by T. Usala; A. Clavenna; M. Bonati; A. Zuddas (S177-S178).
S.08.01 Modulators of NMDA receptors by C. Sur (S178).
S.08.02 Dopamine stabilising drugs by P.G. Strange (S178).
S.08.03 D2 antagonist/5-HT1A agonist interactions by A. Newman-Tancredi (S178-S179).
S.05.01 Dopaminergic agents by P. Cowen (S172).
S.04.08 Clozapine application in prefrontal cortex blocks the effects of systemic MK-801 on extracellular 5-HT and glutamate by X. López-Gil; Z. Babot; M. Amargós-Bosch; C. Suñol; F. Artigas; A. Adell (S172).
S.02.01 Pre-, peri-, and postnatal risk factors and precursors of ADHD by J.K. Buitelaar (S166).
S.01.05 The molecular basis for add-on therapy for psychopathology, cognition and mood in schizophrenia by H.Y. Meltzer; M. Huang; Z. Li; A. Prus (S166).
S.02.02 Abnormal development of brain function in ADHD and effects of methylphenidate by K. Rubia; R. Halari; A.B. Smith; M. Mohammad; E. Taylor (S166-S167).
S.02.03 Genetic vulnerabilities for ADHD by M. Gill (S167).
S.02.04 Atomoxetine and ADHD by D. Purper-Ouakil (S167).
S.01.04 Psycho-education in management of schizophrenia by C. Höschl; L. Motlova (S165-S166).
S.01.03 The treatment of post-psychotic depression by S. Dollfus (S165).
Author Index (S593-S610).
PL.01 Novel signalling paradigms in animal models by M.G. Caron (S163).
PL.03 Interactions of the immune system and the brain by R. Dantzer (S163).
S.01.02 Treating schizophrenic patients with OCD and anxiety by J. Zohar; Y. Sasson; E. Yuven-Wetzler (S165).
S.02.05 Neurocognitive effects of methylphenidate in adult attention deficit/hyperactivity disorder by E.M. Bekker; J.C. Verster; J.L. Kenemans (S167-S168).
S.03.01 Molecular genetic approach in depression by J. Mendlewicz (S168).
S.04.04 Abnormalities in behaviour and reduction in expression of specific hippocampal genes genes by prenatal stress in female offspring are reversed by neonatal handling by Y. Nachum-Biala; S. Salomon; Y. Bogosh; M. Linial; M. Weinstock (S170-S171).
S.04.03 Allosteric changes of the NMDA receptor trap diffusible dopamine 1 receptors in spines by L. Scott; S. Zelenin; S. Malmersjö; J.M. Kowalewski; E. Zettergren-Markus; A.C. Nairn; P. Greengard; H. Brismar; A. Aperia (S170).
S.04.05 Molecular dissection of the role of GABAB1 receptor isoforms 1a and 1b in anxiety-related behaviour by L.H. Jacobson; H.C. Neijt; B. Bettler; K. Kaupmann; J.F. Cryan (S171).
S.04.06 Fluorescence in vitro studies of human dopamine D1 and D2 receptor proteins interaction by A. Faron-Gorecka; J. Andrecka; M. Dziedzicka-Wasylewska; Z. Wasylewski (S171-S172).
S.04.07 Relative expression of tryptophan hydroxylase 1 and 2 in the brain: spatial and temporal analysis by L. Gutknecht; C. Kriegebaum; K.P. Lesch; A. Schmitt (S172).
S.04.02 The role of medial septal NMDA receptors in behavioural functions of the hippocampus in the rat by E. Elvander-Tottie (S170).
S.04.01 Functional proteomic analysis of an animal model of depression combining genetic vulnerability and environmental stress by A. Mallei; R. Giambelli; V.S. Barbiero; A.A. Mathé; A. El Khoury; L. Carboni; E. Domenici; K.J. Aitchison; G. Racagni; M. Popoli (S169-S170).
S.03.02 Gene-environment interaction in depression by K. Sugden; A. Caspi; T.E. Moffitt; I.W. Craig (S168).
S.03.03 mRNA expression in post-mortem studies by J.A. Garcia-Sevilla; D. Arteta; J.J. Meana (S168-S169).
S.03.04 Combining imaging and genotypes in depression: fact or fiction? by P.M. Grasby (S169).
S.03.05 Clinical pharmacogenetic studies in the treatment of depression by A. Serretti (S169).
S.10.02 Genetics of pathological gambling and substance use disorders by D. Comings (S181).
S.10.03 Neuroimaging .ndings in pathological gambling by C. Büchel (S181-S182).
S.20.02 Neuroendocrine controls of sleep by A. Steiger; M. Kimura; M. Kluge; P. Schüssler (S193-S194).
S.20.01 Mechanisms of sleep: focus on serotonergic regulations by G. Bagdy (S193).
S.20.03 Neuropeptide-monoamine interactions in normal and stress-altered sleep by V. Fabre; A. Rachalski; M. Hamon; J. Adrien (S194).
S.20.04 Hypocretin deficiency and narcolepsy by S. Overeem (S194).
S.20.05 Genetic aspects of sleep by M. Tafti (S194-S195).
S.19.05 Heterooligomerization of D1 and D2 dopamine receptors in brain: implications for psychosis? by A.J. Rashid; C.S. So; B.F. O'Dowd; S.R. George (S193).
S.19.04 In vivo imaging of the D2high receptors occupancy by antipsychotics in Schizophrenia by A. Graff; D. Mamo; S. Kapur (S192-S193).
S.18.05 Deep brain stimulation: the new neurosurgery for depression? by A. Lozano (S191).
S.18.04 Repetitive transcranial magnetic stimulation (TMS) by T.E. Schlapfer; M. Kosel (S191).
S.19.01 Psychoses converge via D2high receptors by P. Seeman (S191-S192).
S.19.02 Mechanisms of dopaminergic dysfunction in rats with neonatal ventral hippocampus lesions by L.K. Srivastava; S.K. Bhardwaj; G. Flores; R. Quirion (S192).
S.19.03 Birth injury and the psychosis pathway: insights from animal models of obstetric complications by P. Boksa (S192).
S.21.01 Comparative efficacy and tolerability of antidepressants in anxiety disorders by D.S. Baldwin; K. Ajel (S195).
S.21.03 Can propranolol prevent PTSD? by A.H. Van Stegeren (S195).
S.23.04 Immunotherapy for Alzheimer's disease by D. Schenk; S. Schroeter; M. Buttini; M. Grundman; D. Games; P. Seubert (S198).
S.23.03 Neuroimaging in Alzheimer's disease by N.C. Fox (S197-S198).
S.23.05 New functions for presenilins: do they identify novel therapeutic targets? by F. Checler (S198).
S.24.02 The interaction of hypnotics with synaptic and extrasynaptic GABAa receptors by J. Lambert; D. Belelli; D. Peden; M. Herd (S198).
S.24.03 Role of extrasynaptic GABA in hippocampus by B.A. Orser; L.J. Martin; V.Y. Cheng; R.P. Bonin (S198-S199).
S.23.02 Transgenic animal models of Alzheimer's disease by J. Götz (S197).
S.23.01 Pathogenic mechanisms in Alzheimer's disease by L. Lannfelt; D. Sehlin; H. Englund; A. Lord; A.S. Johansson; L. Nilsson; F. Ekholm-Pettersson (S197).
S.21.05 The beta-3-adrenergic receptor in anxiety disorders and their treatment by J. Stemmelin; C. Cohen; G. Griebel (S195-S196).
S.22.01 Early onset of bipolar disorders by M. Preisig (S196).
S.22.03 Early onset of behavioural disorders by H. Anckarsäter (S196).
S.22.05 Very early onset schizophrenia by J. Rapoport (S196-S197).
S.18.03 Sleep deprivation and light therapy by F. Benedetti (S191).
S.18.02 Vagus nerve stimulation: the heart and guts of the matter by M. Trimble (S190).
S.14.04 CATIE trial results by J.A. Lieberman; T.S. Stroup; J.P. McEvoy; M.S. Swartz; R. Keefe; D.O. Perkins; S. Davis; C.E. Davis; B. Lebowitz; J. Hsiao (S184-S185).
S.14.02 Illicit drugs in schizophrenia by J. Macleod (S184).
S.14.05 Metabolic side effects of antipsychotics by W.W. Fleischhacker (S185).
S.15.01 Atypical antipsychotics: a possible treatment for anxiety? by P. Blier (S185).
S.15.02 Dopamine model of OCD in rats by H. Szechtman; D. Eilam (S186).
S.14.01 Regional brain metabolism (18FDG PET) and polymorphisms for candidate genes in schizophrenia: from SNPs to phenotypes by J. Horacek; F. Spaniel; T. Novak; M. Kopecek; P. Mohr; C. Höschl (S184).
S.11.05 Growth factors in the treatment of neurodegenerative diseases by M. Saarma (S183-S184).
S.10.05 Pharmacological treatment of pathological gambling by A. Ibanez Cuadrado (S182).
S.10.04 Neurocognitive deficits in pathological gambling and related disorders by A.E. Goudriaan; J. Oosterlaan; E. De Beurs; W. Van den Brink (S182).
S.11.01 Common pathological pathways in neurodegenerative brain diseases: the genes involved in Parkinson's disease by A. Brice (S182-S183).
S.11.02 The ubiquitin/proteasome system in neurodegenerative disease by N.P. Dantuma; V. Menéndez-Benito; L.G.G.C. Verhoef (S183).
S.11.03 Can cells repair the brain in Parkinson's disease? by R.A. Barker (S183).
S.15.03 Dopamine and conditioned fear by M.A. Pezze (S186).
S.15.04 Dopaminergic challenges in social anxiety disorder by S.V. Argyropoulos; S.D. Hood; S.J.C. Davies; D.A. Hince; K. Morris; D.J. Nutt; J.P. Potokar (S186).
S.17.03 Clinical and neurobiolological evidence for efficacy of drug treatment in childhood-onset OCD by M.F. Flament; M. Irak; J.C. Bisserbe (S189).
S.17.02 Safety and tolerability of antipsychotics in children and adolescents by C. Arango (S189).
S.17.04 Pharmacological treatment of adolescent depression by D. Cohen (S189-S190).
S.17.05 Is there place for pharmacology in the treatment of childhood anxiety disorders? by B. Vitiello (S190).
S.18.01 Electroconvulsive therapy (ECT) by T. Bolwig (S190).
S.17.01 Pharmacological management of .rst episode adolescent psychosis by J. Fegert; G. Libal; P. Plener (S188-S189).
S.16.05 Blood and brain gene expressions in schizophrenia by M.T. Tsuang; S.J. Glatt; W.S. Kremen; J. Corbeil; R. Sasik; N. Khanlou; M. Han; C.C. Liew; I.P. Everall (S188).
S.15.05 Impulsivity and compulsivity: translational .ndings on the role of dopamine by H.G.M. Westenberg (S187).
S.16.02 Depression: the GENDEP study by U. D'Souza; K. Sugden; K.J. Aitchison; L.C. Schalkwyk; P. McGuffin; M. Pariante (S187).
S.16.03 Chronic fatigue syndrome by J.R. Kerr; R. Petty; B. Burke; D. Fear; J. Montgomery; S.C.M. Richards; M. Thomas; A.P. Smith; T.J. Harrison; P. Kellam; A.T. Holgate (S187-S188).
S.16.04 Peripheral gene expression in PTSD by A.Y. Shalev; R.H. Segman; N. Friedman; N. Kaminski; N. Sheffi; T. Goltser-Dubner (S188).
P.1.d.008 Alterations in the functional activity of the prodynorphin gene expression in selected brain regions are associated to increased preference for ethanol and the development of dependence by J.M. Oliva; A. Lorente; E. Sanguino; J. Manzanares (S253-S254).
P.1.d.009 Possible involvement of GABAA-benzo-diazepine receptor in the anxiolytic-like effect induced by Passiflora actinia extracts in mice by R.M.W. Oliveira; L.F. Lolli; C.A. Santos (S254).
P.2.c.036 A prospective study of the incidence and predictive factors of interferon induced neuropsychiatric disorders in hepatitis C patients by P.C.A. Castellvi; C.D.Q. Díez-Quevedo; R.M.S. Martín-Santos; R.S.L. Solà; R. Navinés; J.A. Galeras (S332).
P.2.c.035 Research update from the latest STAR*D findings by M.H. Trivedi; M. Fava; A.A. Nierenberg; D. Warden; S.R. Wisniewski; A.J. Rush (S331-S332).
P.2.c.037 Depression:characteristics of patients who receive adequate, inadequate, or no treatment at all by O. Zivanovic (S332-S333).
P.2.d.001 Wf-516, a novel antidepressant with dual serotonergic activity: I. Receptor and pharmacological profiles in comparison with reference antidepressants by J. Maeda; Y. Morio; Y. Oohashi; J. Katayama; A. Nishiyama; K. Yamagami; K. Saito (S333).
P.2.d.002 Wf-516, a novel antidepressant with dual serotonergic activity: II. Pharmacological profiles ex vivo and in vivo to monoamine transporters in comparison with standard antidepressant by J. Maeda; Y. Morio; J. Katayama; S. Horie; K. Inaba; A. Nishiyama; J. Eguchi; K. Saito (S333-S334).
P.2.c.034 Escitalopram versus nortriptyline in the treatment of painful physical symptoms in patients with major depression by K. Gattner; J. Jaracz; J. Hauser (S331).
P.2.c.033 Clinical effectiveness of lamotrigine in recurrent major depressive disorder, resistant to other therapies by V. Fricchione Parise (S330-S331).
P.2.c.029 Early sustained improvement with escitalopram leads to high response rates by W.J. Burke; A. Korotzer; K. Saikali (S328-S329).
P.2.c.028 Mirtazapine use during pregnancy - a report of 8 cases by J.-.L. Janu; R.-.S. Rackova (S328).
P.2.c.030 The COX-2 inhibitor celecoxib has therapeutic effects in major depression:results of a double-blind, placebo controlled, add-on study to reboxetine by M.J. Schwarz; S. Dehning; A. Douhe; A. Cerovecki; B. Goldstein-Müller; I. Spellmann; G. Hetzel; K. Maino; H.J. Möller; V. Arolt; M. Riedel; N. Müller (S329).
P.2.c.031 Venlafaxine/mirtazapine-combination in treatment-resistant major depression by H. Ullrich; J.L. Pach; R. Kudling; E. Klieser (S329-S330).
P.2.c.032 Influence of personality and environmental variables on the depressive response of anxiety and depressive patients by M. Vidal Millares; J. Brenlla Gonzalez; M.C. Garcia Mahia; M. Vidal Meijon; J. Mazaira Castro (S330).
P.2.d.003 The effects of fluoxetine on the expression and function of CREB in peripheral T lymphocytes of depressed patients by J.W. Chung; S.W. Lim; J.H. Yoon; H.R. Kim; S. Kim; D.K. Kim (S334).
P.2.d.004 Evaluation of antidepressant activities of rose oil and geranium oil in the forced swim test in mouse by L. Khalaj; D. Farzin (S334-S335).
P.2.d.012 Behavioural and molecular effects of the combined treatment fluoxetine plus acetylsalicylic acid in a rat model of depression by S. Alboni; G. Capone; C. Benatti; F. Tascedda; J.M.C. Blom; J. Mendlewicz; N. Brunello (S339).
P.2.d.011 Effects of the novel antidepressant agomelatine (S 20098) and fluoxetine in chronically stressed tree shrews, an animal model of depression by E. Fuchs; B. Schmelting; E. Mocaër (S338-S339).
P.2.d.013 TC-2216: anti-depressant effects through selective modulation of neuronal nicotinic receptors by P.M. Lippiello; M. Bencherif; G.J. Gatto; K.G. Jordan; V.M. Traina (S339-S340).
P.2.d.014 Effect of the selective COX-2 inhibitor, celecoxib, on brain cytokines in the olfactory bulbectomised rat model of depression by A.M. Myint; L. Goeghegan; D. Luchtman; H.W.M. Steinbusch; B.E. Leonard (S340).
P.2.d.015 Galanin enhances and a galanin antagonist attenuates depression-like behaviour in the rat by E. Kuteeva; T. Wardi; T. Hökfelt; S.O. Ögren (S340-S341).
P.2.d.010 Characterization of post synaptic effects of antidepressant drugs in glial cell model by N. Karni; S. Schreiber-Avissar (S338).
P.2.d.009 Agomelatine, a novel pharmacological approach to treating depression by M. Hamon; M.J. Millan (S337-S338).
P.2.d.005 In vivo electrophysiological assessment of the putative antidepressant Wf-516 in raphe dorsalis, locus coeruleus and hippocampus in the rat brain by M. El Mansari (S335).
P.2.d.006 Serotonin 7 receptor antagonists as putative antidepressants with safer and faster onset of actions by C. Faure; O. Mnie-Filali; E. Gondard; A. Berod; A. Didier; P. Blier; G. Debonnel; N. Haddjeri (S336).
P.2.d.007 Proteomic analysis of hippocampus and frontal cortex in a rat model of depression with gene-environment interaction and antidepressant treatment by L. Carboni; C. Piubelli; M. Vighini; A. El Khoury; S. Gruber; W. Anderssen; A.A. Mathé; K.J. Aitchison; A. Mallei; R. Giambelli; M. Popoli; E. Domenici (S336-S337).
P.2.d.008 Effects of concurrent glucocorticoid receptor blockade using Org34850 on the neurochemical actions of fluoxetine: indications for adjunct therapeutic potential by D.A. Johnson; S.E. Gartside; C.D. Ingram (S337).
P.2.c.027 Suicidal behaviour and psychopharmaco-therapy in urgent psychiatry outpatients department by P. Pregelj (S327-S328).
P.2.c.026 Changes of heart rate variability after antidepressant treatment in psychiatric outpatients by B.K. Son; S.K. Lee (S327).
P.2.c.009 The incidence of antidepressant-associated mania and hypomania in major depression by W.M. Bahk; Y.S. Woo; J.H. Chae; J.H. Choi; T.Y. Jun; K.S. Kim; W. Kim (S317).
P.2.c.008 Is it appropriate to combine conceptually related scores in meta-analyses? - A Monte Carlo simulation approach for antidepressant trials by J. Ballesteros; I. Güemes (S316-S317).
P.2.c.010 Impact of the melatonergic antidepressant agomelatine on sleep-wake rhythms of depressed patients by C. Guilleminault; M.A. Quera-Salva (S317-S318).
P.2.c.011 Effects of a phytopharmacal triple combination of St. John's wort, valerian and passion flower on sleep EEG, cognitive performance and mood: a double-blind randomised cross-over study in healthy volunteers by U.M. Hemmeter; A. Thum; M. Giesler; A. Haag; A. Wartenberg-Demand; G.P. McGregor; B. Kundermann; J.C. Krieg (S318).
P.2.c.012 Favorable sexual profile of agomelatine in depressed patients by S.H. Kennedy (S319).
P.2.c.007 Comparison of bupropion extended release and venlafaxine extended release for the treatment of depression: a double-blind, multicentre trial by A.H. Clayton; M.E. Thase; B.R. Haight; A.E. Harriett; N.E. Richard; E.P. Goodale (S316).
P.2.c.006 Efficacy and safety of bupropion extended release in elderly patients with major depressive disorder by W. Chrzanowski; R. Rousseau; K. Hewett; M.D. Gee; D. Wightman; N.E. Richard; J.G. Modell; E.P. Goodale (S315-S316).
P.2.c.002 Efficacy of milnacipran augmentation of nicotine replacement therapy on post-cessation mood and anxiety in smokers with previous history of major depression by I. Berlin; H.J. Aubin; L. Mansuy; G. Lagrue (S313-S314).
P.2.c.001 Clinical symptoms of major depression are associated with the intensity dependence of auditory evoked ERP components by T. Linka; G. Sartory; B.W. Müller (S313).
P.2.c.003 Maintenance ECT for severely depressed elderly patients by D. Mazeh; D. Paleacu; Y. Barak (S314).
P.2.c.004 Changes in sexual functions under mirtazapine treatment - primary data of a national, multicentre, prospective observational study in depressed patients by P. Osvath; S. Fekete; V. Voros; J. Almasi (S314-S315).
P.2.c.005 Clinical pharmacokinetics of fluoxetine in depressed Parkinsonian patients on mono and combined therapy by I.K. Kovacevic; M.P. Pokrajac; B.M. Miljkovic; M.M. Mijajlovic; E.D. Dzoljic; V.K. Kostic (S315).
P.2.c.013 Antidepressant efficacy of agomelatine 25-50 mg versus venlafaxine 75 -150 mg: two randomized, double blind studies by S.H. Kennedy; C. Guilleminault (S319-S320).
P.2.c.014 A randomized controlled clinical trial comparing “guideline exposed” and “guideline naive” physicians in respect to dosage selection and treatment outcome with doxepin by M. Linden (S320).
P.2.c.022 Mirtazapine versus tricyclic antidepressants for the treatment of depression, anxiety and distressing symptoms of cancer by E.S. Cankurtaran; A.H. Soygur; E. Ozalp; L. Turhan (S324-S325).
P.2.c.021 Antidepressant switch efficacy in selective serotonin reuptake inhibitors resistant major depressive disorder by O. Vasiliu; D. Vasile; M. Miclos; P. Ivanov (S324).
P.2.c.023 A comparison of unipolar depression treatment using antidepressants alone versus using antidepressants in combination with quetiapine (4 year follow-up) by M.Z. Hussain; W. Waheed; S. Hussain (S325).
P.2.c.024 Is mirtazapine in combination with perospirone efficacious in drug resistant depression? - Via 5-HT1A receptor activation by M. Morita; K. Nakayama; R. Nakajyo; A. Kusaka; H. Kodaka; H. Miyata (S325-S326).
P.2.c.025 Gender differences in patient's acceptance of mirtazapine orally disintegrating tablet in Lithuanian clinical practice by V. Danileviciute; V. Adomaitiene (S326).
P.2.c.020 The efficacy of the oestrogen substitution associated with antidepressants in the treatment of menopausal depression by I.A. Dan; M. Grimberg (S323-S324).
P.2.c.019 Two-year maintenance treatment study assessing recurrence prevention with venlafaxine XR in patients with recurrent unipolar major depression by M. Keller; B. Yan; D. Dunner; J. Ferguson; E. Friedman; A. Gelenberg; R.M.A. Hirschfeld; J. Kocsis; S. Kornstein; C. Nemeroff; P. Ninan; A. Rothschild; A. Schatzberg; R. Shelton; M.E. Thase; M.H. Trivedi; J. Zajecka; S. Ahmed; J. Musgnung; R. Pedersen (S322-S323).
P.2.c.015 Effect of mirtazapine for insomnia in patients with major depressive episode: a polysomnographic study by H. Kim; K.J. Lee; S.H. Lee (S320-S321).
P.2.c.016 Antidepressant use and the risk of suicide, attempted suicide and overall mortality in a nation-wide cohort by J. Tiihonen; J. Lönnqvist; K. Wahlbeck; T. Klaukka; A. Tanskanen; J. Haukka (S321).
P.2.c.017 Antidepressant efficacy of agomelatine in major depressive disorder:meta-analysis of three pivotal studies by S.A. Montgomery; J.P. Olie; S.H. Kennedy (S321-S322).
P.2.c.018 Zinc supplementation enhances the therapeutic response in treatment resistant unipolar depression by M. Siwek; D. Dudek; W. Datka; A. Zieba; A. Pilc; G. Nowak (S322).
P.2.d.016 Effects of combined administration of a selective inhibitor of the FAAH (URB597) and imipramine or citalopram in the forced swimming test in rats by M. Filip; M. Frankowska; K. Wydra; E. Nowak; A.C. McCreary (S341).
P.2.d.017 The new antidepressant duloxetine increases BDNF mRNA and protein levels in rat frontal cortex by F. Calabrese; P.F. Maj; A. Cattaneo; M. Gennarelli; G. Racagni; R. Molteni; M.A. Riva (S342).
P.2.g.007 Influence of clock gene polymorphism on sleep-wake cycle in depressed bipolar patients: an actigraphic study by S. Dallaspezia; F. Benedetti; M. Cigala Fulgosi; B. Barbini; C. Colombo; C. Lorenzi; A. Serretti; E. Smeraldi (S361).
P.2.g.006 Disparity in the rate of depression and use of antidepressants in the USA by ethnicity/race: 1992-2003 by D.A. Sclar; T.L. Skaer; L.M. Robison (S360-S361).
P.2.g.008 Serum zinc level as potential marker in recurrent depressive disorder by M. Siwek; D. Dudek; W. Datka; A. Zieba; A. Pilc; G. Nowak (S361-S362).
P.2.g.009 Amisulpride association to selective serotonin reuptake inhibitors in severe major depressive episodes with psychotic features by O. Vasiliu; D. Vasile; S. Paraschiv; M. Miclos; P. Ivanov (S362).
P.2.g.010 A comparison of total direct medical costs to managed care of escitalopram versus citalopram treatment in severe major depressive disorder by M.H. Erder; D. Sharma; J. Jonas (S362).
P.2.g.005 Differences in sertraline treatment between general practitioners and psychiatrists by M. Linden (S360).
P.2.g.004 Severity of depression during the first year of vagus nerve stimulation in the group of non-responders by C. Frick; S. Hosten; D. Brodesser; M. Kosel; N. Axmacher; K.U. Kuehn; S. Brannan; W. Maier; T.E. Schlaepfer (S359-S360).
P.2.f.002 Plasma brain-derived neurotrophic factor and neurocognitive correlates in euthymic bipolar patients: preliminary results by V.V. Dias; S. Brissos; C. Cardoso; A.I. Carita; A. Martinez-Arán; F. Castro (S357).
P.2.f.001 Cognitive functions and neurological soft signs among patients with bipolar disorder, trait or state marker? by M. Rabie; A. Sadek; A. Soliman; H. Ramy (S356-S357).
P.2.g.001 Diagnostic stability in major depressive disorder as according to DSM-IV by W.M. Bahk; Y.S. Woo; J.H. Chae; T.Y. Jun; K.S. Kim (S357-S358).
P.2.g.002 Repetitive transcranial magnetic stimulation for treatment of older patients with depression - an open label trial by R.V. Milev; G. Abraham; R. Sharma (S358).
P.2.g.003 The role of SSRIs in treatment of patients with irritable bowel syndrome by S.T.G. Tosic Golubovic; D.G. Gugleta; N.D. Djordjevic (S359).
P.2.h.001 Cognitive dysfunction in the geriatric depression living in the institution by L. Jung Sik; H.S. Oh; J.W. Park (S363).
P.2.h.002 Plasma levels of nitric oxide metabolites in patients with postpartum depression by B.H. Lee; Y.C. Shin; Y.K. Kim; K.H. Kim (S363-S364).
P.3.a.008 Schizophrenia with catatonic features: a factor analytic study by W. Goggins; G.S. Ungvari; S.K. Leung; F.S. Ng (S368-S369).
P.3.a.007 Measuring catatonia:application of an item response theory model by G.S. Ungvari; E. Wong; S.K. Leung; W.K. Tan (S367-S368).
P.3.a.009 Patients' attitudes to antipsychotic depot medication: adherence, extrapyramidal side effects and needle anxiety by M.X. Patel; N. DeZoysa; M. Bernadt; A.S. David (S369).
P.3.a.010 Risperidone long-acting injection: a one year observational study in a naturalistic setting by M.X. Patel; C. Young; A.S. David; D.M. Taylor (S369-S370).
P.3.a.011 The heterogeneity of functional outcome measures in schizophrenia by J.L. Phillips; A.A. Ledoux; R. Westmacott; P. Boyer (S370).
P.3.a.006 Characteristics of Minnesota multiphasic personality inventory and symptom checklist 90-revision in schizophrenias with aggressive behaviour by S.H. Kang; S.H. Chung; J.Y. Jung; H.Y. Chung; M.H. Kim; H.C. Song; S.H. Kwon; M.J. Sung; Y.S. Jin; S.B. Baek (S367).
P.3.a.005 Exploring the socio-cultural components of prescription patterns in schizophrenia: a comparative study by Y.T. Xiang; Y.Z. Weng; G.S. Ungvari; C.M. Leung; W.K. Tang (S366-S367).
P.3.a.001 Premorbid functioning and its relationship with quality of life of patients with schizophrenia by K. Gorna; K. Jaracz; J. Rybakowski (S364).
P.3.a.002 Elevated plasma copper/zinc ratios in patients with schizophrenia by D. Farzin; N. Mansouri; T. Yazdani (S364-S365).
P.3.a.003 Survey on the acceptance and outcome of oral risperidone for acute psychotic agitation by V. Dubois; Hasoc Investigators' Group (S365).
P.3.a.004 Long acting risperidone in treatment of non-compliant bipolar patients by M. Cetin; C. Basoglu; S.U. Ebrinc; B. Semiz; A. Algul; M. Oguz (S365-S366).
P.2.e.020 Rates of improvement with quetiapine across dimensions of bipolar disorder by A. Ketter (S356).
P.2.e.019 Specificity of effect of quetiapine for depressive symptoms in bipolar disorder by R.M.A. Hirschfeld; J.R. Calabrese (S355-S356).
P.2.e.002 Are atypical antipsychotics associated with a shorter inpatient stay in patients with mania or hypomania? by R. Hodgson; S. Sudharsan (S347).
P.2.e.001 Bipolar diathesis of unipolar treatment resistant depression by W.M. Bahk; Y.S. Woo; J.H. Chae; T.Y. Jun; K.S. Kim; W. Kim (S346-S347).
P.2.e.003 Second generation antipsychotics versus haloperidol in the treatment of acute mania: a meta-analysis by H. Scherk; F.G. Pajonk; S. Leucht (S347).
P.2.e.004 Effect of lamotrigine on concurrent electroconvulsive therapy by P. Sienaert; H. Demunter; K. Vansteelandt; J. Peuskens (S348).
P.2.e.005 Elevated urine Adam12 protein levels in lithium-treated bipolar patients by Y. Bersudsky; C. Nadri; R.H. Belmaker; G. Agam (S348-S349).
P.2.d.024 5-HT1A receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats: clinical implications by S.J. Sukoff Rizzo; L.E. Schechter; S. Rosenzweig-Lipson (S345-S346).
P.2.d.023 Different types of potassium channels underlie the antidepressant-like effect of adenosine in the mouse forced swimming test by M.P. Kaster; J. Budni; A.R.S. Santos; A.L.S. Rodrigues (S345).
P.2.d.019 Antidepressant-like effect of the acute administration of folic acid in mice by P.S. Brocardo; J. Budni; M.P. Kaster; A.R.S. Santos; A.L.S. Rodrigues (S343).
P.2.d.018 Antidepressant-like effects of gabapentin and GABA-lactam analogues in the forced swimming test and in the tail suspension test by M. Mantovani; M.P. Kaster; T.J. Feuerstein; A.L.S. Rodrigues (S342-S343).
P.2.d.020 Antidepressant-like effect of guanosine in the forced swimming test and in the tail suspension test by M.P. Kaster; K.M. Bonetti; A.R.S. Santos; A.L.S. Rodrigues (S343-S344).
P.2.d.021 Chronic agomelatine and fluoxetine treatments induce antidepressant effects in H/Rouen mice, a new genetic mouse model of depression by M. El Yacoubi; B. Coupé; C. Gabriel; E. Mocaër; J. Costentin; J.M. Vaugeois (S344).
P.2.d.022 The modified Tail Suspension Test (mTST): a new paradigm to categorize antidepressants. Effects of classical and atypical opiates by E. Berrocoso; J. Gibert-Rahola; M.D. De Benito; J.A. Micó (S344-S345).
P.2.e.006 Outcomes of acute mania: 12 months results from the European mania in bipolar longitudinal evaluation of medication (EMBLEM) study by J.M. Haro; I.A. Goetz; J. Bertsch; E. Vieta; J. Van Os (S349).
P.2.e.007 Dopamine function in bipolar depressed patients by J.A. Monreal Ortiz; F. Duval; M.C. Mokrani; G. Pinault; S. Fattah; N. Chokmani; J. He; C. Champeval; J.P. Macher (S349-S350).
P.2.e.015 The efficacy and tolerability of quetiapine monotherapy in acute mania by B. Yoon; W.M. Bahk; J. Lee; S. Won; S. Lee; K. Min; D. Jon; S. Chung (S353-S354).
P.2.e.014 A new tool to detect lithium-induced glomerular nephropathy by T.J. Raedler; S. Wittke; H. Jahn; D. Schoettle; H. Mischak; K. Wiedemann (S353).
P.2.e.016 Antipsychotic treatments during acute mania with prominent aggressive behaviour by A. González-Pinto; J.A. Micó; F. Mosquera; C. González; A. Aldama; S. Barbeito; P. Vega; C. Matute; E. Vieta (S354).
P.2.e.017 Safety, tolerability and ef .cacy of rapidly-initiated quetiapine in acutely ill patients with bipolar I disorder by I. Cobo; J. Hernandez; F. Vazquez-Gutierrez; J.L. Galan; M. Tafalla (S354-S355).
P.2.e.018 Management of side effects associated with new treatments for depressive symptoms in bipolar disorder by J.R. Calabrese; R.M.A. Hirschfeld; K.D. Wagner (S355).
P.2.e.013 Symptoms of bipolarity in patients with eating disorders by F. Rybakowski; K. Kaminska (S352-S353).
P.2.e.012 New-Deli: a twelve-week, open, randomisedtrial comparing sodium valproate to lithium in patients with bipolar 1 disorder by J.K. Rybakowski (S352).
P.2.e.008 Validity and reliability of the Spanish version of the Bech-Rafaelsen's mania (MAS) and melancholia (MES) scales for bipolar disorders by J. Bobes; E. Vieta; J. Ballesteros; A. González-Pinto; A. Luque; N. Ibarra (S350).
P.2.e.009 Body weight changes in patients with acute mania treated with combination of mood stabilizer and atypical antipsychotic or typical antipsychotic by M.H. Kang; J.S. Jeon; C.E. Kim; J.S. Lee; J.N. Bae (S350-S351).
P.2.e.010 A new rat model for evaluation of efficacy and time point for onset of action for antidepressants by M.N. Jayatissa; A. Bergstroem; T. Christensen; C. Bisgaard; O. Wiborg (S351).
P.2.e.011 Aggressive behaviour during acute mania: a cross-sectional study with 173 different manic patients by F. Mosquera; S. Barbeito; E. Garcia del Moral; S. Alvarez de Eulate; P. Lopez; M. Casado; A. González-Pinto (S351-S352).
P.2.b.020 Lack of association between gender and antidepressant response in Major Depression by A.C. Altamura; A. Santini; S. Zanoni; E. Mundo (S312).
P.2.b.019 Behavioural characterization of mice knockout for the nociceptin/orphanin FQ receptor gene in animal models of anxiety by E.C. Gavioli; G. Marzola; G. Calo (S311-S312).
P.1.e.027 Imaging neural interactions during social information processing in schizophrenia by D. Baas; A. Aleman; N.F. Ramsey; E.H.F. De Haan; R.S. Kahn (S274).
P.1.e.026 A 3 T BOLD functional MRI study of the neural underpinnings of depression by A. Bernasconi; F. Benedetti; V. Blasi; M. Cadioli; C. Colombo; S. Dallaspezia; A. Falini; D. Radaelli; G. Scotti (S273-S274).
P.1.f.001 Cognitive testing in early-phase clinical trials: development of a rapid computerized test battery and application in a simulated Phase I study by A. Collie; A. Darekar; P. Maruff; P. Snyder; J.P. Huggins (S274-S275).
P.1.f.002 Treatment of bulimia nervosa with citalopram: a randomized controlled trial by C. Siano; W. Milano; C. Petrella; P. Renzi; A. Capasso (S275).
P.1.f.003 Treatment of binge eating disorder with sertraline: a randomized controlled trial by C. Siano; W. Milano; C. Petrella; P. Renzi; A. Capasso (S275).
P.1.e.025 Prediction of response to high frequency repetitive transcranial magnetic stimulation (HF-rTMS) in treatment resistant depression (TRD): preliminary results from PET brain imaging by C. Baeken (S273).
P.1.e.024 Progesterone modulates the serotonergic influence on autobiographic memory in healthy men by C.J. Spindelegger; R. Lanzenberger; M. Mitterhauser; L.K. Mien; P. Strzelecka; W. Wadsak; U. Moser; N. Klein; A. Holik; T. Attarbaschi; J. Sacher; N. Mossaheb; T. Geiss-Granadia; K. Kletter; S. Kasper (S272).
P.1.e.020 Hippocampal serotonin-1A receptor binding correlates with cortisol plasma levels in social anxiety disorder by R. Lanzenberger; W. Wadsak; C. Spindelegger; M. Mitterhauser; N. Klein; L.K. Mien; T. Attarbaschi; N. Mossaheb; J. Sacher; A. Holik; T. Geiss-Granadia; K. Kletter; S. Kasper (S270).
P.1.e.019 Reduction of prefrontal gray matter volume in first-episode schizophrenia independent of risperidone treatment by T. Kasparek; R. Prikryl; D. Schwarz; H. Kucerova; M. Mikl; E. Ceskova; P. Krupa (S269-S270).
P.1.e.021 Neural correlates of emotional self in bipolar disorder: a BOLD functional MRI 3 T study by D. Radaelli; F. Benedetti; A. Bernasconi; V. Blasi; M. Cadioli; C. Colombo; S. Dallaspezia; A. Falini; G. Scotti; E. Smeraldi (S270-S271).
P.1.e.022 Effects of attention and emotion on face processing in depression: a functional MRI study by M.J. Desseilles; S. Schwartz; T.T. Dang-Vu; V. Sterpenich; A. Darsaud; G. Albouy; G. Vandewalle; S. Gais; M. Schabus; G. Rauchs; C. Degueldre; A. Luxen; M. Ansseau; P. Maquet (S271).
P.1.e.023 Functional MRI investigation using visual and emotional memory induction paradigms in chronic depression by A.V. Ravindran; A. Smith; C. Cameron; R. Bhatla; I. Cameron (S271-S272).
P.1.f.004 Neurocognitive function in patient with Hwa-byung and major depressive disorder by J.H. Choi; S.H. Lee; Y.H. Yun; C.H. Han (S275-S276).
P.1.f.005 Psychological structure of patients with diabetes by K.M.K. Michelidakis (S276).
P.1.g.001 Increased CSF cholecystokinin, NPY and GABA levels in pathological gambling by C. Nordin; I. Sjödin (S280-S281).
P.1.f.012 The effect of soy phytoestrogens on mental rotation by I. Riecansky; L. Pilsakova; D. Ostatnikova; F. Jagla (S280).
P.1.g.002 The orexin A plasma levels in patients with restrictive type of anorexia nervosa by M. Janas-Kozik; I. Krupka-Matuszczyk; M. Matuszczyk (S281).
P.1.g.003 Two cases of the induction of EEG seizure during long-term rapid-rate TMS by T. Zyss; A. Zieba; D. Dudek; B. Sawicki; A. Krawczyk; M. Siwek (S281-S282).
P.1.g.004 Serum MIF as marker for immune processes in schizophrenia by L. De la Fontaine; M.J. Schwarz; M. Riedel; P. Zill; N. Müller (S282).
P.1.f.011 Global impairment in the controlled access to the episodic autobiographical memory in depression: state or trait marker? by L. Bergouignan; C. Lemogne; D. Vitoli; J.F. Allilaire; P. Fossati (S279).
P.1.f.010 Event-related potentials and secondary task performance during simulated driving performance by A.E. Wester; K.B.E. Böcker; E.R. Volkerts; J.C. Verster; J.L. Kenemans (S279).
P.1.f.006 High frequency repetitive TMS over the right dorsolateral prefrontal cortex: influence on Stroop task performance by M.A. Vanderhasselt; R. De Raedt; C. Baeken; P. Clerinx; L. Leyman; H. D'haenen (S276-S277).
P.1.f.007 Alexithymia in severe obese patients by V. Marechal; G. Loas; A. Legrand; J.L. Monestes; M. Corcos (S277).
P.1.f.008 The effects of emotion on sustained attention in patients with schizophrenia by S.H. Park; S.K. An (S278).
P.1.f.009 Dysfunction of configural face processing in schizophrenia by T.H. Ha; M.H. Na; J.S. Kwon (S278).
P.1.e.018 Action monitoring and psychotic ego-disturbances: a functional MRI model to link selected psychopathologic symptoms to regional physiological dysfunctions by K. Schnell; K. Heekeren; J. Daumann; T. Schnell; A. Neukirch; W. Möller-Hartmann; V. Heßelmann; E. Gouzoulis-Mayfrank (S268-S269).
P.1.e.017 Hippocampal volume in post traumatic stress disorder: effects of traumatic event and sertraline treatment by L. Bossini; M. Tavanti; S. Calossi; A. Lombardelli; N. Polizzotto; R. Galli; G. Vatti; F. Pieraccini; P. Castrogiovanni (S268).
P.1.d.018 Effect of dopamine depletion and 5-HT1B receptors blockade on the behavioural effect of various antidepressant in the mice FST by F. Chenu; E. Dailly; M. Bourin (S259).
P.1.d.017 Participation of the ventral hippocampus in the modulation of anxiety: role of nitric oxide, Rizzi A., et al., in the 2002, Br. behaviour of J. Pharmacol, 136, rats evaluated in the 303-311. elevated T-maze by A.V. Calixto; M.S. Faria; T.C.M. De Lima (S258-S259).
P.1.e.001 Fusiform gyral volumes over two time points in adolescent-onset schizophrenia by A. James; S.M.C. James; D.M. Smith; C. Day (S259-S260).
P.1.e.002 Prefrontal brain function in healthy controls and patients with ADHD by A.J. Fallgatter; C.G. Baehne; A.C. Ehlis; M.M. Richter; K.P. Lesch; M.M. Plichta (S260).
P.1.e.003 DTNBP1 (dysbindin) gene variants modulate prefrontal brain function in healthy individuals and schizophrenic patients by A.J. Fallgatter; M.J. Herrmann; C. Hohoff; A.C. Ehlis; T.A. Jarczok; C.M. Freitag; J. Deckert (S260).
P.1.d.016 The effects of a selective serotonin reuptake inhibitor and a tricyclic antidepressant on the behaviour of chronically stressed 129SvemJ and C57BL/6J mice in the hole board and forced swim test by E. Binder; J.L. Paya-Cano; F. Sluyter; L.C. Schalkwyk (S258).
P.1.d.015 Nociceptin and [Nphe1, Arg14, Lys 15]-nociceptin-NH2, UFP-101 restored opioid antinociception in morphine tolerant mice by S. Pieretti; A. Di Giannuario (S257-S258).
P.1.d.011 Anxiolytic-like effects of NMDA-receptor antagonist injected into the ventral but not dorsal hippocampus in rats submitted to the elevated plus maze by L.P.N. Hackl; A.P. Carobrez (S255-S256).
P.1.d.010 A dopaminergic mechanism recruited in the anti-punitive effect of the DOI in the four-plates test-retest paradigm by N. Ripoll; M. Hascoet; M. Bourin (S254-S255).
P.1.d.012 Propranolol restores the anxiolytic action of midazolan during the retest in the elevated plus maze test by C.A.J. Stern; K. Ward; C. Anzini; A.P. Carobrez (S256).
P.1.d.013 Memory performance of dopamine D3 knock-out mice (KO) mice pre-treated with beta-amyloid peptide is affected by cannabinoid CB1 receptor antagonist by V. Micale; G.M. Leggio; C. Mazzola; A. Tamburella; F. Drago (S256-S257).
P.1.d.014 Learned helplessness in the lines of helpless (H/Rouen) and nonhelpless (NH/Rouen) mice - effect of short-term treatment with imipramine and fluoxetine by M. El Yacoubi; J. Blot; B. Coupé; J. Costentin; J.M. Vaugeois (S257).
P.1.e.004 Cingulate glutamatergic signals distinguish adult patients with ADHD from healthy controls - a magnetic resonance spectroscopy study by E. Perlov; A. Philipsen; B. Hesslinger; M. Buechert; D. Ebert; L. Tebarzt van Elst (S261).
P.1.e.005 Near infrared reflectance spectroscopy (NIRS) -guided inhibitory repetitive TMS treatment of auditory verbal hallucinations in schizophrenias by A.J. Fallgatter; B. Warrings; A.C. Ehlis; M.M. Richter; C.G. Baehne; M.M. Plichta (S261).
P.1.e.013 No differences in the ratio of dopamine transporter availability of putamen and caudate nucleus between patients with combined and with inattentive type of ADHD by K.H. Krause; C. La Fougére; J. Krause; M. Ackenheil; S. Dresel (S265-S266).
P.1.e.012 The single-voxel proton magnetic resonance spectroscopy in recurrent depression - a pilot study by A. Silczuk; D. Dudek; M. Siwek; T. Zyss; A. Werewka-Maczuga; B. Sobiecka; J. Kozub; A. Urbanik; A. Zieba (S265).
P.1.e.014 The effects of lorazepam on extrastriatal dopamine D2/3-receptors - a positron emission tomography study with [11C]FLB 457 by H. Vilkman; J. Kajander; S. Aalto; T. Vahlberg; K. Någren; T. Allonen; E. Syvälahti; J. Hietala (S266).
P.1.e.015 Changing of dopamine transporter binding in depressed patients with anhedonia during treatment by G. Camardese; D. Di Giuda; V. Carli; A. Picello; G. Di Carlo; L. Mosca; C. Morelli; R. Rossetti; A. Giordano; P. Bria (S267).
P.1.e.016 Intersubject differences in reappraisal strategies of negative emotion: a functional MRI study by R. Viviani; K. Ehrhard; H. Lo; A.B. Horn (S267-S268).
P.1.e.011 Effect of the acute tryptophan depletion on the neural response to happy and sad faces by P. Fusar Poli; P. Allen; F. Lee; S. Surguladze; N. Tunstall; C. Fu; M. Brammer; A. Cleare; P. McGuire (S264-S265).
P.1.e.010 Multivariate voxel-based morphometry to map structural characteristics associated with gender differences in schizophrenia by Y. Kawasaki; M. Suzuki; T. Takahashi; M. Kurachi (S264).
P.1.e.006 Using a contextual binding task as a probe to explore hippocampal activation in schizophrenia: fMRI studies by L.J. Boulay; J.L. Phillips; P. Boyer (S261-S262).
P.1.e.007 Atypical and typical antipsychotics differentially reverse abnormal brain functional MRI signals in a neurodevelopmental model of schizophrenia by J.L. Moreau; K. Jeanneau; C. Risterucci (S262).
P.1.e.008 Hypothalamic decrease in serotonin1A receptor binding indicating disturbances in the hypothalamic-pituitary-gonadal axis in anxiety disorders by U. Moser; C.J. Spindelegger; R. Lanzenberger; L.K. Mien; M. Mitterhauser; W. Wadsak; N. Klein; T. Attarbaschi; A. Holik; N. Mossaheb; J. Sacher; K. Kletter; S. Kasper (S263).
P.1.e.009 Low-resolution electromagnetic tomography (LORETA) source imaging compared with structural brain imaging in patients having organic brain lesion by S.H. Lee; G.H. Kwon; Y.M. Park; H. Kim; K.J. Lee; Y.C. Chung (S263-S264).
P.1.g.005 Psychotic disorders and serotonin transporter: supporting evidences from blood cell studies by S. Baroni; G. Giannaccini; B. Dell'Osso; C. Carmassi; D. Marazziti (S282).
P.1.g.006 New findings on the purported mechanism of action of vagus nerve stimulation in treatment-resistant depression by C.D. Kilts; S. Brannan; R. Van Woensel (S283).
P.2.b.002 Depressive-like phenotype in mice lacking cannabinoid CB1 receptors by O. Valverde; E. Aso; A. Ozaita; E. Valdizán; A. Pazos; R. Maldonado (S302-S303).
P.2.b.001 Expression of genes related to 5-HT neurotransmission: regulation by citalopram in a rat model of depression by G. Flugge; R. Abumaria; R. Rygula; E. Fuchs (S302).
P.2.b.003 Chronic mild stress induces depressive behaviours: role for AMPA receptors and brain-derived neurotrophic factor by E. Toth; R. Gersner; D.E. Dar; I. Akirav; I. Musseri; A. Zangen (S303).
P.2.b.004 Functional activity of α2-adrenoceptors in postmortem frontal cortex of depressed suicide victims by R. Diez-Alarcia; E.M. Valdizan; J. Gonzalez-Maeso; J.A. Garcia-Sevilla; A. Pazos; J.J. Meana (S303-S304).
P.2.b.005 Effect of chronic electroconvulsive shocks on Bcl-2 immunoreactivity in frontal cortex and nucleus accumbens by K. Basar; T. Dalkara; M. Rezaki (S304).
P.2.a.035 Clinical characteristics of depressive episodes in Bipolar I and Bipolar II disorders by S. Linotte; M. Barreto; N. Van Geit; H. D'haenen; P. Vanderkelen; N. Schepers; G. Scantamburlo; W. Pitchot; M. Ansseau; K. Van der Auwera; J. Bollen; D. Souery; J. Mendlewicz (S301).
P.2.a.034 RAPSODY registry of patients with painful symptoms and observation of depression and anxiety by A. Mignon; P. Linkowski; C. Van Heeringen; M. Dramaix; S. Leyman (S300-S301).
P.2.a.030 Fatigue correlates in major depression: preliminary findings by P.P. Ferentinos; V.P. Kontaxakis; B.J. Havaki-Kontaxaki; D.G. Dikeos; C.R. Soldatos (S298-S299).
P.2.a.029 Psychopathology of sexual function: categorical or dimensional approach? by L. Bossini; M. Valdagno; N. Polizzotto; G. Capano; P. Castrogiovanni (S298).
P.2.a.031 Serotonin transporter promoter genetic characterization: possible pharmacogenetic implications of rare alleles by A. Pirovano; C. Lorenzi; P. Aartioli; E. Marino; M. Catalano; E. Smeraldi (S299-S300).
P.2.a.032 Paroxetine in the treatment of dysthymic disorder without major depression - efficacy, tolerability, and impact on quality of life by A.V. Ravindran; C. Cameron; R. Bhatla; S. Simpson (S300).
P.2.a.033 Effectiveness of maintenance therapy of bipolar disorders in a naturalistic setting: preliminary data by A. Tundo; F. Marchetti; I. Lega (S300).
P.2.b.006 Allosteric modulation of GABAB receptor coupling in rat brain: G-protein subtype dependence revealed by immunocapture scintillation proximity assays by C. Mannoury La Cour; C. Herbelles; M.J. Millan (S304-S305).
P.2.b.007 Reduced complexity of cardiovascular regulation in major depressive disorder by S. Boettger; D. Hoyer; K. Falkenhahn; M. Kaatz; K.J. Bar (S305).
P.2.b.015 The infralimbic cortex modulates stress-induced coping behaviour - implications for depression by D.A. Slattery; J.F. Cryan (S309-S310).
P.2.b.014 Does the antidepressive response to opiate treatment describe a subtype of depression? by P.W. Nyhuis; M. Specka; M. Gastpar (S309).
P.2.b.016 Evaluation of reward processes in an animal model of depression by D.A. Slattery; A. Markou; J.F. Cryan (S310).
P.2.b.017 Biologic epistasis between SERT and BDNF: complex genetic mechanisms of depression by L.P. Pezawas; A.L. Goldman; B.A. Verchinski; V.A. Mattay; J.H. Callicott; B.S. Kolachana; R.E. Straub; M.F. Egan; A. Meyer-Lindenberg; D.R. Weinberger (S310-S311).
P.2.b.018 Impaired cognitive inhibition and verbal memory in association with the STin2 polymorphism of the serotonin transporter gene in major depression by A. Sárosi; G.K. Balogh; E. Dömötör; M. Sasvári-Székely; A. Székely; G. Faludi (S311).
P.2.b.013 Neuropeptides in human cerebrospinal fluid and in brains of animal models of depression - effects of treatment by A.A. Mathé; G. Nikisch; H. Agren; P. Baumann; A. El Khoury; S.H.M. Gruber; H. Husum; P. Jiménez-Vasquez; G. Wortwein; W. Andersson; K.J. Aitchison; P. McGuffin (S308-S309).
P.2.b.012 Neurochemical basis of the sociability trait: behavioural profiles and differences in extracellular serotonin levels in rats with high and low sociability by J. Harro; A. Alttoa; M. Tõnissaar; T. Mällo; K. Kõiv; M. Eller (S308).
P.2.b.008 Antidepressant-like activity of Wf-516, an antagonist of 5-HT1A receptors and inhibitor of 5-HT reuptake, in a chronic mild stress model of depression in rat by M. Papp; P. Gruca; E. Litwa; M. Lason; E. Przegalinski (S305-S306).
P.2.b.009 The activity of dopamine transporter (DAT) in depression and the effect of sertraline - preliminary results by β-CIT SPECT by M. Árgyelán; Z. Szabó; S. Kéri; Z. Besenyi; L. Pávics; Z. Janka (S306).
P.2.b.010 Oxytocin, vasopression and anxiety in major depression: ago-antagonist neurohormones by G. Scantamburlo; M. Hansenne; S. Fuchs; W. Pitchot; J. Reggers; P. Marechal; E. Pinto; M. Ansseau; J.J. Legros (S306-S307).
P.2.b.011 Copper as trait marker of major depressive episode by M. Fontana; R. Squitti; S. Cesaretti; M.G. Bevacqua; M. Ventriglia; M. Ribolsi; P.L. Zuppi; P.M. Rossini (S307-S308).
P.2.a.028 Mania, hypomania, and suicidality: findings from a prospective community study by T. Bronisch; L. Schwender; M. Hoefler; H.U. Wittchen; R. Lieb (S297-S298).
P.2.a.026 Persistent verbal episodic memory deficits in recurrent depressed patients despite response to antidepressant treatment: preliminary results by A. Radtchenko; W. Choucha; M. Asch; A.M. Ergis; P. Fossati; J.F. Allilaire (S297).
P.2.a.009 Natural killer T cell patients with major depressive disorder by Y.W.J. Jeon; S.I.H. Han; E.J.P. Park (S287-S288).
P.2.a.008 The influence of antidepressants on anabolic balance in depression by Y. Kochetkov; L.N. Gorobets (S287).
P.2.a.010 L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression by D. Lojko; J.K. Rybakowski (S288).
P.2.a.011 A systematic review and meta-analysis on the efficacy of brief psychotherapies and pharmacotherapy in the acute treatment of depression by J. Ballesteros; I. Göemes; M.A. González-Pinto; J.R. Rueda; I. Querejeta; A. Retolaza (S288-S289).
P.2.a.012 Cortisol hypersecretion in unipolar major depression with melancholic and psychotic features: dopaminergic, noradrenergic and thyroid correlates by F. Duval; M.C. Mokrani; J.A. Monreal-Ortiz; S. Fattah; C. Champeval; J.P. Macher (S289).
P.2.a.007 “Difficult depression” at private psychiatric clinics throughout France: an epidemiological survey (DEDICACE survey) by T. Bougerol; A. Gérard; P. Bouhours; V. Moreau-Mallet (S286-S287).
P.2.a.006 Comparison of bifrontal and unilateral ultra-brief pulse electroconvulsive therapy for depression by P. Sienaert; K. Vansteelandt; K. Demyttenaere; J. Peuskens (S286).
P.2.a.002 A geriatric depression scale detects depression in Hong Kong Chinese elderly patients with pneumoconiosis? by W.K. Tang; C.M. Lum; G.S. Ungvari; H.F.K. Chiu (S283-S284).
P.2.a.001 The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder by Y. Kim; K.M. Lee (S283).
P.2.a.003 Treatment resistant depression: response to prednisolone supression test by M.F. Juruena; A.S. Papadopoulos; L. Poon; S. Lightman; A.J. Cleare; C.M. Pariante (S284-S285).
P.2.a.004 Memory, attention and executive functions in melancholic versus non-melancholic depression by C. Even; C. Monier; J. Thuile; F. Rouillon; J.D. Guelfi (S285).
P.2.a.005 Severe depression without ICD-10 somatic syndrome does exist: clinical characteristics and diagnostic efficiency of somatic symptoms by J. Thuile; C. Even; F. Rouillon; J.D. Guelfi (S285-S286).
P.2.a.013 Chronobiological thyroid axis dysfunction in depression by M.C. Mokrani; F. Duval; J.A. Monreal Ortiz; C. Champeval; D. Maurice; J.P. Macher (S290).
P.2.a.014 Rapid effect of escitalopram in a behavioural model of depression: the chronic escape deficit by G. Capone; S. Alboni; C. Benatti (S290).
P.2.a.022 Escitalopram in the treatment of obsessive-compulsive disorder by D.J. Stein; B. Tonnoir; E.W. Andersen; N. Fineberg (S295).
P.2.a.021 Depression and socio-economic status: an 8-year longitudinal population-based study by V. Lorant; C. Croux; S. Weich; D. Deliége; J. Mackenbach; M. Ansseau (S294-S295).
P.2.a.023 Maternal suicidality and risk of suicidality in offspring: findings from a community study by R. Lieb; T. Bronisch; M. Hoefler; A. Schreier; H.U. Wittchen (S295-S296).
P.2.a.024 Results of the European multi-centre study (D03) of vagus nerve stimulation in treatment-resistant depressive patients by C. Frick; S. Hosten; M. Kosel; D. Brodesser; N. Axmacher; K.U. Kuehn; S. Brannan; M. Kreft; A. Zobel; W. Maier; T.E. Schlaepfer (S296).
P.2.a.025 Predictors of response to vagus nerve stimulation by D. Brodesser; C. Frick; S. Hosten; N. Axmacher; M. Kosel; K.U. Kuehn; S. Brannan; W. Maier; T.E. Schlaepfer (S296-S297).
P.2.a.020 High cholesterol, triglycerides, and body-mass index in suicide attempters: a population-based study by J. Brunner; T. Bronisch; H. Pfister; F. Jacobi; M. Hoefler; H.U. Wittchen (S293-S294).
P.2.a.019 An actigraphic registration of depressed patients treated with chronotherapeutics by A. Pontiggia; F. Benedetti; B. Barbini; M. Cigala Fulgosi; C. Colombo; S. Dallaspezia; E. Smeraldi (S293).
P.2.a.015 Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study by D. Michelson; L.A. Adler; J.D. Amsterdam; D.L. Dunner; A.A. Nierenberg; F.W. Reimherr; A.F. Schatzberg; D.K. Kelsey; P.D. Feldman; L.R. Levine; D.W. Williams (S290-S291).
P.2.a.016 Depression in Chinese patients with Parkinson's and clinical determinants by W.K. Tang; D.M.L. Chan; H.F.K. Chiu; G.S. Ungvari; K.S. Wong; V. Mok (S291-S292).
P.2.a.017 Escitalopram in relapse prevention in patients with obsessive-compulsive disorder (OCD) by N. Fineberg; O. Lemming; B. Tonnoir; D.J. Stein (S292).
P.2.a.018 Bupropion efficacy in major depressive disorder and alcohol dependence dual diagnosis by D. Vasile; M. Sarmache; M.L. Vasile; M.D. Gheorghe (S292-S293).
Editorial Board (ii).